Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED]  
Document Date:  11-Feb-2019A Phase 3, Multicenter, Randomized, Double-blind, Active 
Comparator -controlled Study to Evaluate the Safety and Tolerability 
of V114 in Healthy Infants (PNEULINK)
PRODUCT: V114  1
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD).
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind, Active Comparator -
controlled Study  to Evaluate the Safet y and Tolerability  of V114 in Healthy Infants (PNEU -
LINK)
Protocol Number: 031-01
Compound Number: V114
Sponsor Name:
[CONTACT_19519] & Dohme Corp., a subsidiary  of [COMPANY_006] & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One [COMPANY_006] Drive
[PO_BOX]
Whitehouse Station, New Jersey , [ZIP_CODE] -0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND
EudraCT14115
2018- 003308
-38
Approval Date: [ADDRESS_832270]: V114  2
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide b y all provisions of this protocol.
Typed Name:
[CONTACT_1641]:Date 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  3
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
DOCUMENT HISTORY
Document Date of Issue Overall Rationale
V114 -031-00 06- Sep-2018 Original pr otocol
V114 -031-01 11- Feb-2019 Amendment to add opsonophagocy tic activity  (OPA) testing to the Premature Infant 
Immunogenicit y Substudy 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  4
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
PROTOCOL AMENDMENT S UMMARY OF CHANGES
Amendment: 01
Overall Rationale for the Amendments:
The main purpose for this protocol amendment is to add opsonophagocy tic activity (OPA) testing to the Premature Infant 
Immunogenicit y Substudy .
Summary of Changes Table:
Section # and Name [CONTACT_624772]. 
The correct EudraCT number is: 
2018- 003308- 38.Updated for accuracy
Section 3:Hypotheses, Objectives, 
and EndpointsAn exploratory  objective was added for the 
Premature Infant Immunogenicity  Substudy
to evaluate anti -PnPs seroty pe-specific 
opsonophagocy tic activity  (OPA) 
geometric mean titers (GMTs)Updated to align with addition of OPA testing 
to the Premature Infant Immunogenicit y 
Substudy
Section [IP_ADDRESS] :Immunogenicity  
Endpoints
Section 8.2:Immunogenicity  
AssessmentsAdded information on the multiplexed 
opsonophagocy tic assay (MOPA) .MOPA is another method for evaluating the 
immune response to pneumoc occal conjugate 
vaccines (PCVs). This assay  is being added to 
complement the pneumococcal 
electrochemiluminescence (PnECL) assay . 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  5
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Section # and Name [CONTACT_9353] 9.4.1: Immunogenicity  
Endpoints
Section 9.6.1: Statistical Methods 
for Immunogenicit y Analy sesAdded OPA GMT as exploratory  
immunogenicit y endpoint.Updated to align with addition of OPA 
responses as an exploratory  endpoint for the 
Premature Infant Immunogenicity  Substudy .
Section 9.9.1: Sample Size and 
Power for Immunogenicity  
Analy sesThe sample size assumptions for the 
Premature Infant Immunogenicity  Substudy  
were clarified.
The text “prior PD4” was revised to “prior 
to Dose 4” in this section for clarit y.Revised for clarity .
Section 10.3.4: Recording AE and 
SAE, Assessment of intensityClarified the reporting period for injection -
site AEs evaluated b y maximum size. 
Original Text :
Injection site redness or swelling from the 
day of vaccination through Day  5 
postvaccination will be evaluated by  
[CONTACT_75367].
Revised Text :
Injection site redness, swelling, or hard 
lump from the day  of vaccination through 
Day 14 postvaccination will be evaluated 
by [CONTACT_624753].Revised for accuracy  and alignment with the
primary  objective of the protocol (Section 3).
Section 10.7.1: Country -specific 
request for Malay siaAdded a general safet y hypothesis based on 
feedback from Malay sia.Addition of safet y hypothesis is necessary  to 
conduct the study  in Malay sia. 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  6
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Section # and Name [CONTACT_9353] 10.8: Abbreviations Added abbreviations for MOPA and OPA. Revised for completeness.
Throughout Minor e ditorial revisions Changes are minor and have not been 
summarized i ndividually . 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  7
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT S UMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 14
1.1 Synopsis ................................................................................................................. 14
1.2 Schema .................................................................................................................. 18
1.3 Schedule of Activities (SoA) ................................................................................ 19
2 INTRODUCTION .......................................................................................................... 24
2.1 Study Rationale ....................................................................................................24
2.2 Background .......................................................................................................... 24
2.2.1 V114 and Pneumococcal Disease ................................................................ 24
2.2.2 Preclinical and Clinical Studies ...................................................................25
2.2.3 Information on Other Study -related Therap y.............................................. 25
2.3 Benefit/Risk Assessment ...................................................................................... 26
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 26
4 STUDY DESIGN ............................................................................................................ 27
4.1 Overall Design ......................................................................................................27
4.2 Scientific Rationale for Study Design ................................................................ .28
4.2.1 Rationale for Endpoints ............................................................................... 29
[IP_ADDRESS] Immunogenicit y Endpoints ................................................................ 29
[IP_ADDRESS] Safety  Endpoints ................................................................................ 30
[IP_ADDRESS] Future Biomedical Research .............................................................. 30
4.2.2 Rationale for the Use of Comparator ........................................................... 30
4.3 Justification for Dose ........................................................................................... 31
4.4 Beginning and End of Study Definition ............................................................. 31
4.4.1 Clinical Criteria for Early Study Termination ............................................. 31
5 STUDY POPULATION ................................................................................................ 31
5.1 Inclusion Criteria ................................................................................................ .31
5.2 Exclusion Criteria ................................................................................................ 32
5.3 Lifestyle Considerations ...................................................................................... 34
5.4 Screen Failures .....................................................................................................34
5.5 Participant Replacement Strategy ......................................................................34
6 STUDY INTERVENTION ............................................................................................ 34
6.1 Study Intervention(s) Administered ...................................................................34
6.2 Preparation/Handling/Storage/Accountability ................................................. [ADDRESS_832271]: V114  8
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
6.2.2 Handling, Storage, and Accountability ........................................................ 36
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. 37
6.3.1 Intervention Assignment.............................................................................. 37
6.3.2 Stratification ................................................................................................ .37
6.3.3 Blinding........................................................................................................37
6.4 Study Intervention Compliance .......................................................................... 38
6.5 Concomitant Therapy .......................................................................................... 38
6.5.1 Rescue Medications and Supportive Care ................................................... 39
6.6 Dose Modification (Escalation/Titration/Other) ............................................... [ADDRESS_832272] to Follow -up................................................................................................ .41
8 STUDY ASSESSME NTS AND PROCEDURES ........................................................ 41
8.1 Administrative and General Procedures ........................................................... 42
8.1.1 Informed Consent ......................................................................................... 42
[IP_ADDRESS] General Informed Consent ................................................................ .42
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 43
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_832273] .....................................................................43
8.1.4 Medical History ........................................................................................... 43
8.1.5 Prior and Concomitant Medications Review ............................................... 44
[IP_ADDRESS] Prior Medications ............................................................................... 44
[IP_ADDRESS] Concomitant Medications ..................................................................44
8.1.6 Assignment of Screening Number ............................................................... 44
8.1.7 Assignment of Treatment/Randomization Number .....................................44
8.1.8 Study  Intervention Administration .............................................................. 45
[IP_ADDRESS] Timing of Dose Administration ......................................................... [ADDRESS_832274] Questionnaire ................................................................ 47
8.1.12 Discontinuation and Withdrawal ................................................................ .47
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 47
8.1.13 Participant Blinding/Unblinding ..................................................................[ADDRESS_832275]: V114  9
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
8.1.14 Calibration of Equipment ............................................................................. 48
8.2 Immunogenicity Assessments ............................................................................. 48
8.2.1 Pneumococcal Electrochemiluminescence .................................................. 49
8.2.2 Multiplex Opsonophagocytic Assay ............................................................ 49
8.3 Safety Assessments ............................................................................................... 50
8.3.1 Physical Examinations ................................................................................. 50
8.3.2 Body Temperature Measurements ............................................................... 50
8.3.3 Safety  Assessment and Use of the eVRC .................................................... 51
8.3.4 Clinical Safety  Laboratory  Assessments ..................................................... 51
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events .................................................................................... 51
8.4.1 Time Period and Frequency  for Collecting AE, SAE, and Other 
Reportable Safet y Event Information .......................................................... 52
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safet y Events ......53
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety  Event Information ...53
8.4.4 Regulatory  Reporting Requirements for SAE ............................................. 54
8.4.5 Pregnancy  and Exposure During Breastfeeding .......................................... 54
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_832276] (ECI s)................................................................ 54
8.5 Treatment of Overdose ........................................................................................ 54
8.6 Pharmacokinetics................................................................................................ .55
8.7 Pharmacodynamics .............................................................................................. 55
8.8 Future Biomedical Research Sample Collection ............................................... 55
8.9 Planned Genetic Analysis Sample Collection .................................................... 55
8.10 Biomarkers ........................................................................................................... 55
8.11 Medical Resource Utilization and Health Economics .......................................55
8.12 Visit Requirements ............................................................................................... 55
8.12.1 Screening......................................................................................................55
8.12.2 Treatment Period/Vaccination Visit ............................................................ 55
8.12.3 Discontinued Participants Continuing to be Monitored in the Study .......... 56
9 STATISTICAL ANALYSIS PLAN ............................................................................. 56
9.1 Statistical Analysis Plan Summary.....................................................................56
9.2 Responsibility for Analyses/In -house Blinding ................................................. 58
9.3 Hypotheses/Estimation ........................................................................................ [ADDRESS_832277]: V114  10
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
9.5 Analysis Populations ............................................................................................ 59
9.5.1 Immunogenicit y Analysis Populations ........................................................ 59
9.5.2 Safety Anal ysis Populations ........................................................................60
9.6 Statistical Methods ............................................................................................... 60
9.6.1 Statistical Methods for Immunogenicit y Anal yses......................................61
9.6.2 Statistical Methods for Safety Anal yses...................................................... 61
9.6.3 Demographic and Baseline Characteristics ................................................. 63
9.7 Interim Analyses ..................................................................................................64
9.8 Multiplicity ........................................................................................................... 64
9.9 Sample Size and Power Calculations ................................................................ .64
9.9.1 Sample Size and Power for I mmunogenicity  Analy ses............................... 64
9.9.2 Sample Size and Power for Safet y Anal yses............................................... 65
9.10 Subgroup Analyses ............................................................................................... 66
9.11 Compliance (Medication Adherence) ................................................................ .66
9.12 Extent of Exposure ............................................................................................... 66
10 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS .....................................................................................................67
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........[ADDRESS_832278] for Clinical Trials ............................................................. 67
10.1.2 Financial Disclosure ..................................................................................... 69
10.1.3 Data Protection ............................................................................................. 69
[IP_ADDRESS] Confidentiality  of Data ......................................................................70
[IP_ADDRESS] Confidentiality  of Participant Records ............................................... 70
[IP_ADDRESS] Confidentiality  of IRB/IEC I nformation ............................................ 70
10.1.4 Committees Structure ................................................................................... 70
[IP_ADDRESS] Scientific Advisory  Committee .......................................................... 70
[IP_ADDRESS] Executive Oversight Committee ........................................................ 70
[IP_ADDRESS] External Data Monitoring Committee ............................................... 71
10.1.5 Publication Policy ........................................................................................ 71
10.1.6 Compliance with Study  Registration and Results Posting Requirements ...71
10.1.7 Compliance with Law, Audit, and Debarment ............................................ 72
10.1.8 Data Qualit y Assurance ............................................................................... 72
10.1.9 Source Documents ....................................................................................... 73
10.1.10 Study  and Site Closure ................................................................................. 74
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 75
10.3 Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ........................................... [ADDRESS_832279]: V114  11
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
10.3.2 Definition of SAE ........................................................................................ 77
10.3.3 Additional Events Reported .........................................................................78
10.3.4 Recording AE and SAE ............................................................................... 78
10.3.5 Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ........................................................................................................82
10.4 Appendix 4: Devic e Events, Adverse Device Events, and Medical 
Device Incidents: Definitions, Collection, and Documentation ....................... 84
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testin g........................ 85
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research ............................................................................................ 86
10.7 Appendix 7: Country -specific Requirements .................................................... [ADDRESS_832280] for Malay sia....................................................... 91
10.8 Appendix 8: Abbreviations ................................................................................. [ADDRESS_832281]: V114  12
PROTOCOL/AMENDMENT N O.:031-[ADDRESS_832282] OF TABLES
Table 1 Study  Interventions .................................................................................... 35
Table 2 Reporting Time Periods and Time Frames for Adverse Events and 
Other Reportable Safet y Events ................................................................ .53
Table 3 Analy sis Strategy  for Immunogenicit y Variables ......................................61
Table 4 Analy sis Strategy for Safety  Parameters .................................................... 63
Table 5 Within -Group 95% CI s for Vary ing Hy pothetical IgG GMCs and 
Vary ing Standard Deviations .....................................................................65
Table 6 Differences in Incidence of Adverse Event Rates Between the 2 
Vaccination Groups That Can be Detected With an ~80% Probability  
(Assuming 2- sided 5% Alpha Level with 2000 Participants in V114 
Group and 400 Participants in Prevnar 13™ Group) ................................ .[ADDRESS_832283]: V114  13
PROTOCOL/AMENDMENT N O.:031-[ADDRESS_832284]: V114  14
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
1PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind, Active Comparator -
controlled Study  to Evaluate the Safet y and Tolerability  of V114 in Healthy Infants (PNEU -
LINK)
Short Title: Safet y and tolerability  of V114 in healthy  infants
Acronym: PNEUmococcal Conjugate Vaccine Trials: V114 -031(PNEU -LINK)
Hypotheses, Objectives ,and Endpoints :
There is no formal hy pothesis testing in this study.
The following objectives and endpoints will be evaluated in health y infants enrolled at 
approximately  2 months of age (from 42 to 90 days [inclusive]) admini stered V114 or 
Prevnar 13™:
Primary  Objectives Primary  Endpoints
-Objective: To evaluate the safe ty and 
tolerability  of V114 with respect to the 
proportion of participants with adverse 
events (AEs).Following an y vaccination with V114:
-Solicited injection -site AEs from Day  1 
through Day  14 postvaccination
-Solicited sy stemic AEs from Day  1 
through Day 14 postvaccination
-Vaccine -related serious adverse events 
(SAEs) through completion of study 
participation
Secondary  Objectives Secondary  Endpoints
-Objective (Premature Infant 
Immunogenicit y Substudy only): To evaluate 
the anti -pneumococcal poly saccharide (PnPs) 
seroty pe-specific Immunoglobulin G (IgG) 
Geometric Mean Concentrations (GMCs) at 
30 day s following Dose 3, prior to Dose 4 
and at 30 day s following Dose 4 for each 
vaccination group.-Anti-PnP seroty pe-specific IgG responses 
for the 15 serot ypes contained in V114 at 
30 day s postdose 3 (PD3), prior to Dose 4 
(Predose 4) and at 30 days postdose 4 
(PD4) 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  15
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
-Objective (Premature Infant 
Immunogenicit y Substudy onl y): To evaluate 
the anti -PnPs seroty pe-specific IgG response 
rates (proportion of participants meeting 
seroty pe-specific IgG threshold value of 
≥0.35 μg/mL ) at 30 days following Dose 3 
for each vaccination group.-Anti-PnP seroty pe-specific IgG response 
rates for the 15 serot ypes contained in 
V114 at 30 day s PD3
Overall Desig n:
Study  Phase Phase [ADDRESS_832285] participant’s last study -related telephone call or 
visit.
For purposes of analy sis and reporting, the overall study  
ends when the Sponsor receives the last laboratory result 
or at the time of final contact [CONTACT_26355], 
whichever comes last. 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  16
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Number of Participant s:
Approximately  2,400 participants will be randomly  assigned to receive either V114 or 
Prevnar 13™ in the following ratios based on gestational age:
Full-term infants (gestational age ≥37 weeks) 5: 1to V114 or Prevnar 13™
Premature infants (gestational age <37 weeks) 1:1 to V114 or Prevnar 13™
Intervention Groups and Du ration :
Intervention 
Group sIntervention 
Group Name [CONTACT_624773] .Vaccination 
Regimen Use
V114 V114Refer to 
IB4 doses IMSingle dose 
at Visits 1, 2, 
3, and 5 (~2, 
4, 6, and 12 
to 15 months 
of age, 
respectively)Experi
mental
Prevnar 13™Prevnar 1
3™Refer to 
product 
labeling4 doses IMSingle dose 
at Visits 1, 2, 
3, and 5 (~2, 
4, 6, and 12 
to 15 months 
of age, 
respectively)Experi
mental
Admin. = administration; IB = Investigator’s Brochure; IM = intramuscular
Total Number 2 intervention groups
Duration of 
ParticipationEach participant will participate in the study  for approximately  16 to 20 
months from the time the participant’s legall y acceptable representative 
signs the Informed Consent Form (ICF) through the final contact.
Study Governance Committees:
Steering Committee No
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee No
Study  governance considerations are outlined in Appendix 1. 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  17
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Study Accepts Healthy Volunteers :Yes
A list of abbreviations used in this document can be found in Appendix 8. 
  055BNR
055BNR
06DW3Y
PRODUCT: V114 18
PROTOCOL/AMENDMENT N O.:031-[ADDRESS_832286]: V114 19
PROTOCOL/AMENDMENT N O.:031-01
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
1.3 Schedule of Activities (SoA)
Study Period Intervention Follow -up Comments
Months of age is 
calculated according 
to the participant’s 
birth date. Visit Number: 1 TC 2 TC 3 TC 4b5 TC 6 TC
Scheduled Time: Age: ~2 
months
(Dose 1 )Day 15 
after 
Dose 1Age: ~4 
months
(Dose 2 )Day 15 
after 
Dose 2Age: ~6 
months
(Dose 3 )Day 15 
after 
Dose 3~1 
month 
after 
Dose 3Age: ~12 
to 15 
months
(Dose 4 )Day 15 
after 
Dose 4~1 
month 
after 
Dose 4~6 
months 
after 
Dose 4
Visit Window:a≥42 
days of 
age to 
≤[ADDRESS_832287] X
Inclusion/Exclusion Criteria X
Medical History X
Post-Enrollment Procedures
Assignment of Randomization 
NumberX
Prior/Concomitant Medication 
and Non study Vaccination 
ReviewX X X X X X X X X XSee Section 8.1.5 for 
details.
V114 or Prevnar 13™ 
Administration (Blinded)
X X X XAtthese visits , 
participants will 
receive either a single 
dose of V114 or 
Prevnar 13™. 
  055BNR
055BNR
06DW3Y
PRODUCT: V114 20
PROTOCOL/AMENDMENT N O.:031-01
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Study Period Intervention Follow -up Comments
Months of age is 
calculated according 
to the participant’s 
birth date. Visit Number: 1 TC 2 TC 3 TC 4b5 TC 6 TC
Scheduled Time: Age: ~2 
months
(Dose 1 )Day 15 
after 
Dose 1Age: ~4 
months
(Dose 2 )Day 15 
after 
Dose 2Age: ~6 
months
(Dose 3 )Day 15 
after 
Dose 3~1 
month 
after 
Dose 3Age: ~12 
to 15 
months
(Dose 4 )Day 15 
after 
Dose 4~1 
month 
after 
Dose 4~6 
months 
after 
Dose 4
Visit Window:a≥42 
days of 
age to 
≤[ADDRESS_832288] AEs, 
body temperature 
measurements, 
concomitant 
medications, and 
nonstudy vaccinations. 
Instructions for using 
the eVRC will be 
reviewed with the 
participant’s legally 
acceptable 
representative. 
  055BNR
055BNR
06DW3Y
PRODUCT: V114 21
PROTOCOL/AMENDMENT N O.:031-01
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Study Period Intervention Follow -up Comments
Months of age is 
calculated according 
to the participant’s 
birth date. Visit Number: 1 TC 2 TC 3 TC 4b5 TC 6 TC
Scheduled Time: Age: ~2 
months
(Dose 1 )Day 15 
after 
Dose 1Age: ~4 
months
(Dose 2 )Day 15 
after 
Dose 2Age: ~6 
months
(Dose 3 )Day 15 
after 
Dose 3~1 
month 
after 
Dose 3Age: ~12 
to 15 
months
(Dose 4 )Day 15 
after 
Dose 4~1 
month 
after 
Dose 4~6 
months 
after 
Dose 4
Visit Window:a≥42 
days of 
age to 
≤[ADDRESS_832289]-
dose 4
Review eVRC Data with 
Participant’s Legally 
Acceptable RepresentativeX X X X X X X X XSee Section 8.1.[ADDRESS_832290]: V114 22
PROTOCOL/AMENDMENT N O.:031-01
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Study Period Intervention Follow -up Comments
Months of age is 
calculated according 
to the participant’s 
birth date. Visit Number: 1 TC 2 TC 3 TC 4b5 TC 6 TC
Scheduled Time: Age: ~2 
months
(Dose 1 )Day 15 
after 
Dose 1Age: ~4 
months
(Dose 2 )Day 15 
after 
Dose 2Age: ~6 
months
(Dose 3 )Day 15 
after 
Dose 3~1 
month 
after 
Dose 3Age: ~12 
to 15 
months
(Dose 4 )Day 15 
after 
Dose 4~1 
month 
after 
Dose 4~6 
months 
after 
Dose 4
Visit Window:a≥42 
days of 
age to 
≤[ADDRESS_832291]-
dose 4
Body Temperature 
MeasurementX X X XEach participant’s body 
temperature must be 
taken before 
vaccination (see 
Section 8.3.2 for details
on the method of 
temperature 
collection ). Participants 
who have febrile illness 
occurring at or within 
72hours of Visit [ADDRESS_832292] be rescheduled 
(see Section 5.2 for 
details). 
30-Minute Postvaccination 
Observation PeriodX X X XTo be performed by 
[CONTACT_63502].
AE Monitoring X X X X X X X X X X XNonserious AEs are to 
be reported from Days 
1 through 14 following 
each vaccination. SAEs 
and deaths are to be 
reported throughout the 
duration of an 
individual’s study 
participation.
Immunogenicity Procedures 
Serum for I mmunogenicity 
Assays (I ncluding Retention 
Serum) (Premature Infant 
Immunogenicity Substudy
Only)X X XBlood samples must be 
collected before study 
vaccination when 
applicable. 
  055BNR
055BNR
06DW3Y
PRODUCT: V114 23
PROTOCOL/AMENDMENT N O.:031-01
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Study Period Intervention Follow -up Comments
Months of age is 
calculated according 
to the participant’s 
birth date. Visit Number: 1 TC 2 TC 3 TC 4b5 TC 6 TC
Scheduled Time: Age: ~2 
months
(Dose 1 )Day 15 
after 
Dose 1Age: ~4 
months
(Dose 2 )Day 15 
after 
Dose 2Age: ~6 
months
(Dose 3 )Day 15 
after 
Dose 3~1 
month 
after 
Dose 3Age: ~12 
to 15 
months
(Dose 4 )Day 15 
after 
Dose 4~1 
month 
after 
Dose 4~6 
months 
after 
Dose 4
Visit Window:a≥42 
days of 
age to 
≤[ADDRESS_832293] Buccal Swabs for 
Future Biomedical Research XBuccal swab DNA 
samples for analysis 
should be obtained 
prior to the vaccination 
on Visit 1 , on 
randomized 
participants only, or at 
a later date as soon as 
the informed consent is 
obtained.
AE = adverse event; DNA = deoxyribonucleic acid; eVRC = electronic vaccination report card; SAE = serious adverse event
a For calculating the visit windows, the day of vaccination is considered Day 1. To calculate visit windows for subsequent vaccinations, confirm participant date of birth and 
ensure the age of the participant will fall within the appropriate age range for each study visit.
b Visit [ADDRESS_832294]: V114  24
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
2INTRODUCTION
[COMPANY_006] Sharp & Dohme Corp. (MSD) is developi[INVESTIGATOR_63464] 15 -valent 
pneumococcal conjugate vaccine (PCV) (referred to as V114) for the prevention of 
pneumococcal disease caused by  [CONTACT_63504]. V114 contains the 13 serot ypes 
(1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in the licensed vaccin e Prevnar 
13™ (pneumococcal 13 -valent conjugate vaccine [diphtheria CRM 197protein], Wy eth 
Pharmaceuticals, a subsidiary of [COMPANY_007], Inc., Philadelphia, PA), plus 2 additional serotypes 
(22F, 33F).
2.1 Study Rationale
Despi[INVESTIGATOR_96631] y of PCVs , pneumococcal disease remains a concern as non -vaccine 
seroty pes began to appear in increasing frequency  in invasive pneumococcal disease (IPD)
isolates. Given the importance of pneumococcal disease worldwide , the evolving serot ype 
distribution
, and the value of multiple suppliers to strengthen global supply , there is a 
continued need to develop new PCVs with expanded serot ype coverage. V114 includes 2 key 
additional serotypes compared with Prevnar 13™ andwill address an unmet medical and 
public health need for a PCV with expanded coverage. 
This clinical study, to be conducted in healthy  infants approximat ely 2 months of age (42 to 
90 day s of age), is part of a Phase 3 pediatric clinical program to s upport an initial 
registration of V114 for use in healt hy infants and children for the prevention of 
pneumococcal disease caused by  [CONTACT_941] 13 pneumococcal seroty pes contained in Prevnar 13™ 
and 2 additional unique serotypes (22F and 33F) in V114.
The primary  purpose of this study  is to evaluate the safet y and tolerability  of a 4- dose 
schedule (3 doses in the infant primary  series followed by  1 toddler dose) of V114 as 
compared to Prevnar 13™ .The study  sample size was selected to complement other studies 
in the V114 pediatric clinical development program to creat e a robust safety  database to 
characterize the safet y profile of V114. Immunogenicity  of V114 in full -term infants will be 
evaluated in other studies within the V114 clinical development program. In this study , 
premature infants (gestational age <37 weeks) will be included in the Premature Infant 
Immunogenicit y Substudy , which will include immunogenicit y and safet y assessments 
following administration of V114 or Prevnar 13™ . Immunogenicit y and safety data from 
premature infants will be pooled across the V11 4 clinical program to evaluate the safet y and 
immunogenicit y of V114 in this population .
2.2 Background
2.2.1 V114 and Pneumococcal Disease
Refer to the Investigator’s Brochure (IB) for V114 for detailed background, including 
information on pneumococcal disease burden. 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  25
PROTOCOL/AMENDMENT N O.:031-[ADDRESS_832295] incorporated licensed PCVs (eg, Prevnar 13™ and/or 
Synflorix™ (pneumococcal polysaccharide conjugate vaccine [adsorbed], GlaxoSmithKline 
Biologicals S.A, Rixensart, Belgium ) into their infant immunization programs. Prevnar™ 
was first licensed in 2000 and later replaced b y Prevnar 13™ in 2009 (European Union) and 
2010 ([LOCATION_002]). Synflorix™ was licensed in the European Union in 2009. Although 
Prevnar 13™ is indicated for children and adults, Sy nflorix™ is only  indicated for children 
up to [ADDRESS_832296] protection [Centers for Disease 
Control and Prevention 2008] [Ruckinger, S., et al 2009] [Farrell, D. J, et al 2007] [Pi[INVESTIGATOR_63466], 
Tamara, et al 2010] [Lexau, C. A., et al 2005] [Metlay, J. P., et al 2006] [Whitney , Cynthia 
G., et al 2003] [Moore, M. R., et al 2015] [ Lepoutre, A., et al 2015] [Weiss, S., et al 2015] 
[Martinelli, D., et al 2014] [Guevara, M., et al 2016] [Waight, P. A., et al 2015] [Jokinen, J., 
et al 2015] [Palmu, A. A., et al 2015] [Wagenvoort, G. H., et al 2016] .Despi[INVESTIGATOR_6831], an 
increase in the burden of IPD caused b y serotypes not contained in currently available 
vaccines has been observed.
V114 contains all the pneumococcal serot ypes contained in Prevnar 13™ plus 2additional 
seroty pes (22F, 33F). The selection of 22F and 33F was primarily  based on the emergence of 
these 2 serot ypes as important causes of IPDin the era of Prevnar™ and Prevnar 13™. 
Approximately  4 years after inclusion of Prevnar™ in the United Stat es infant immunization 
schedule, serot ypes 22F and 33F accounted for approximately  13% of IPD cases in children 
<5 years of age (incidence rate of I PD due to 22F and 33F combined of 3.1 cases per 100,000 
person -years [PY]), in contrast to 1.3% of IPD cases in the pre -PCV7 era (incidence rate of 
22F and 33F IPD of 1.2 cases per 100,000 PY) [Hicks, L . A., et al 2007] . By 2013 , both 22F 
and 33F were among the leading serot ypes causing IPD bey ond those already  includ ed in 
Prevnar 13™, accounting for approximately 21% of all I PD in children <5 y ears of age in the 
United Stat es [Moore, M. R., et al 2015] .
The additional serot ypes contained in V114 will provide broader covera ge against the leading 
seroty pes associated with pneumococcal disease worldwide. V114 is designed to meet 
continuing medical and public health needs for PCVs globall y, as well as address the 
emergence of pneumococcal disease caused b y serotypes not contain ed in currentl y licensed 
PCVs.
2.2.2 Preclinical and Clinical Studies
Refer to the IB for information on completed preclinical and clinical studies conducted with 
V114.
2.2.3 Information on Other Study -related Therapy
Refer to approved labeling for detailed background information on Prevnar 13™ and other 
licensed pediatric vaccines administered concomitantly. 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  26
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Prevnar 13™ contains the 7 pneumococcal serotypes included in Prevnar™ (4, 6B, 9V, 14, 
18C, 19F, 23F) plus 6 additional serotypes (1, 3, 5, 6A, 7F, and 19A).
Prevnar™ and Prevnar 13™ are also known as Prevenar™ and Prevenar 13™ in many  
countries outside of the U nited States; these vaccines will be referred to as Prevnar™ and 
Prevnar 13™ throughout this document.
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants in clinical studies will directly  benefit from 
treatment during participation, as clinical studies are designed to provide information about 
the safet y and efficacy of an investigational medicine.
Approximately  17% of participants will receive 4 doses of Pr evnar 13™, the standard of 
care, as the active comparator in this study. V114 is expected to provide comparable immune 
responses and a comparable safet y profile to Prevnar 13™ for the shared pneumococcal 
seroty peswhile providing additional coverage for the 2 serot ypes (22F and 33F) unique to 
V114. I t is unknown if the investigational V114 will have the same benefit/risk profile as 
Prevnar 13™.
Additional details regarding specific benefits and risks for participan ts participating in this 
clinical study  may  be found in the accompanyi ng IB and informed consent documents.
3HYPOTHESE S, OBJECTIVES ,AND ENDPOINTS
There is no formal hy pothesis testing in this study.
The following objectives and endpoints will be evaluated in health y infants enrolled at 
approximately  2 months of age (from 42 to 90 days [inclusive]) admini stered V114 or 
Prevnar 13™:
Objectives Endpoints
Primary
•Objective : To evaluate the safet y and 
tolerability  of V114 with respect to the 
proportion of participants with adverse 
events (AEs).Following an y vaccination with V114:
•Solicited injection -site AEs from Day  
1 through Day  14postvaccination
•Solicited sy stemic AEs from Day  1 
through Day  14 postvaccination
•Vaccine -related serious adverse events 
(SAEs) through completion of study  
participation 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  27
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Objectives Endpoints
Secondary
•Objective (Premature Infant 
Immunogenicity Substudy only):To 
evaluate the anti -pneumococcal 
polysaccharide (PnPs) seroty pe-specific 
Immunoglobulin G (IgG) Geometric 
Mean Concentrations (GMCs) at 30 day s 
following Dose 3, prior to Dose 4 and at 
30 day s following Dose 4 foreach 
vaccination group.•Anti-PnP seroty pe-specific IgG 
responses for the [ADDRESS_832297] dose 
3 (PD3) , prior to Dose 4 (
Predose 4 ) 
and at 30 days postdose 4 (PD4)
Objective (Premature Infant 
Immunogenicity Substudy only):To 
evaluate the anti -PnPs seroty pe-specific 
IgG response rates (proportion of 
participants meeting seroty pe-specific 
IgG threshold value of ≥0.35 μg/mL) at 
30days following Dose 3 foreach 
vaccination group.Anti-PnP seroty pe-specific IgG 
response rates for the 15 seroty pes 
contained in V114 at 30 day s PD3
Exploratory
Objective (Premature Infant 
Immunogenicity Substudy only) : To 
evaluate the anti -PnPs seroty pe-specific 
opsonophagocy tic activity  (OPA) GMTs 
at30 day s following Dose 3, prior to 
Dose 4 and at 30 day s following Dose 4
foreach vaccination group . Anti-PnPs seroty pe-specific OPA 
responses for the 15 serotypes 
contained in V114 at 3 0 day s PD3, 
Predose 4 and at 30 day s PD4
4 S TUDY DESIGN
4.1 Overall Design
Approximately  2,400 healthy  infants will be randomly  assigned to receive V114(n=~2,000) 
or Prevnar 13™ (n=~400) at Visits 1, 2, 3, and 5 ( approximately  2, 4, 6, and 12 to 15 months 
of age, respectivel y)in the following ratios based on gestational age :
Full-term infants (gestational age ≥37 weeks) 5:1 to V114 or Prevnar 13™
Premature infants (gestational age <37 weeks) 1:1 to V114 or Prevnar 13™ 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  28
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
It is estimated that approximately  1to 2% of the overall study  population will have a 
gestational a ge <37 weeks andwill be eligible for inclusion in the Premature Infant 
Immunogenic ity Substudy . There is no prespecified number of premature infants targeted for 
enrollment in the substudy .
Participants will be followed for local and s ystemic AEs through Day  14 following each 
vaccination with V114 or Prevnar 13™. Information for SAEs a nd deaths, regardless of 
whether the events are considered to be vaccine -related by  [CONTACT_093], will be collected 
from the time consent is signed through completion of participation in the study . An external 
Data Monitoring Committee (DMC) will condu ct a periodic review of safety and tolerability  
data for the V114 Phase [ADDRESS_832298] blood samples for immunogenicity  assay s drawn at 3 timepoints: (1) 
30 day s Postdose 3(PD3) , (2) immediatel y prior to Dose 4 , and (3) 30 days Postdose 4
(PD4) .
After completion of immunogenicity  testing , serum samples will be stored to conduct an y 
additiona l study -related testing as required by [CONTACT_252323]. For 
randomized study  participants who provided consent for future biomedical research, leftover 
sera from the study  may  be used for the development and/or validation of pneumococcal
assay s after completion of all study -related immunogenicity  testing.
Specific procedures to be performed during the study , as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Section 8.
4.2 Scientific Rationale for Study Design
Health yinfants are at increased risk for pneumococcal disease and its associated morbidity  
and mortality  [Drijkoningen, J. J 2014] .This study will be conducted in healthy infants 
approximately  2months of age (42 to 90 day s of age) ,with premature infants (gestational 
age <37 weeks) comprising approximately  1to 2% of the overall study  population .This will
allow asses sment of the saf ety and tolerability  of V114 in a popula tion that is representative 
of children receiving licensed PCVs in many  countries throughout the world .Safety  data 
collected this study will be pooled with safet y data from similar studies in the V114 pediatric 
clinical development program to create a comprehensive V114 safet y database. 
Premature infants enrolled in the study will be stratified into the Premature Infant Substudy , 
which includes immunogenicity  assessments atthe completion of the primary  series ( after 
Dose 3 of V114 or Prevnar 13™ ),as well as before and after Dose 4 of V114 or 
Prevnar 13™ . Previous studies have shown that premature infants demonstrate a reduced 
response to conjugate v accines [Esposito, S., et al 2005] [Moss, S. J., et al 2010] and that 
gestational age may  affect the ability  of preterm infants to generate a protective immune  
  055BNR
055BNR
06DW3Y
PRODUCT: V114  29
PROTOCOL/AMENDMENT N O.:031-[ADDRESS_832299] S. pneumoniae following receipt of PCV s [Shinefield, H., et al 2002] .These 
data, together with the increased risk of IPD in premature infants [Hausdorff, W. P., et al 
2000] ,highlight the importance of evaluating PCV immune responses in this populat ion. 
Immunogenicit y and safety data from these infants will be pooled with similar data from 
other studies in the V114 clinical development program to characterize the safet y and 
immunogenicit y of V114 in premature infants.
The immunogenicit yand safet y endpoints, including the duration of the safety follow -up 
period, are consistent with previous studies evaluating the immunogenicity and safet y of 
PCVs in an infant population . This study  will also contribute to the overall safet y database 
and immunogenicit y profile of V114 to support initial licensure in infants.
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Immunogenicity Endpoints
Sera from participants in the Premature Infant Immunogenicit y Substudy will be used to 
measure vaccine -induced anti -PnPs seroty pe-specific immune responses for all 15 seroty pes 
included in V114. The p neumococcal electrochemilumine scence (PnECL) assay  and the 
multiplexed opsonophagocytic assay (MOPA) will be used to evaluate immune responses in 
the Premature Infant Immunogenicity Substudy .PnECL  measures serot ype-specific IgG 
GMCs (secondary endpoint ), and MOPA measure sseroty pe-specific OPA GMTs
(exploratory  endpoint). OPA GMTs represent functional antibodies capable of inhibiting 
growth of S. pneumoniae in culture. Additional information on the immunogenicity  assay s 
can be found in Section 8.2.
It is anticipated that not all participants in the Premature Infant Immunogenicity Substudy 
will have sufficient serum to conduct both PnECL and MOPA; therefore ,priority  will be 
given to the PnECL assessment, and the PnECL  assay  will be used to test the secondary  
immunogenicit y hypotheses in this study .
The use of the serot ype-specific IgG antibody  level of ≥0.35 µg/mL  has been recommended 
by a W orld Health Organization (WHO) expert panel as an acce ptable threshold value for 
evaluating the clinical performance of PCV s following a routine childhood vaccination 
regimen [World Health Organization 2008] [ World Health Organization 2005] .The response 
rate (ie, the proportion of participants meeting the seroty pe-specific IgG threshold value of 
≥0.35 μg/mL ) isa secondary  endpoint in the Premature Infant Immunogenicity  Substudy .
Anti-PnPs seroty pe-specific IgG and OPA responses will be measured at 3 time points:
Approximately  30 day s following Dose 3 to evaluate the immune response to the 
primary  vaccination series in premature infants (IgG GMCs, IgG response rates, and 
OPA GMTs) 
Immediately  prior to Dose 4 to evaluate the per sistence of protective immunity in 
premature infants (IgG GMCs and OPA GMTs)  
  055BNR
055BNR
06DW3Y
PRODUCT: V114  30
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Approximately 30 day s following Dose 4 to evaluate anamnestic antibody  responses
in premature infants (IgG GMCs andOPA GMTs) 
Details on the immunogenicity  endpoints evaluated in this study  can be found in 
Section 9.4.1.
[IP_ADDRESS] Safety Endpoints
The safet y endpoints evaluated in this study  were selected based on the product’s safet y 
profile demonstrated in previous studies, published data from marketed PCVs, and feedback 
received from regulatory  agencies during produc t development. The electronic Vaccination 
Report Card (eVRC) used to record AEs during the postvaccination periods, as defined in 
Section 8.1.9, was structured as recommended in the final Food and Drug Administration 
Patient Reported Outcome Guidance [U.S. Food and Drug Administration 2009] .
Details on the safet y endpoints evaluated in this study  can be found in Section 8.3.3 and 
Section 9.4.2.
Details on AEs, including definitions and reporting requirements, can be found in 
Appendix 3.
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct future biomedical r esearch on specimens for which consent was 
provided during this study . This research may  include genetic anal yses (DNA), gene 
expression profiling ( ribonucleic acid [ RNA ]), proteomics, metabolomics (serum, plasma), 
and/or the measurement of other analy tes, depending on whi ch specimens are consented for 
future biomedical r esearch.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study ) and will only  be conducted on specimens from 
appropriatel y consented participants. The objective of collecting/retaining specimens for 
future biomedical r esearch is to explore and identify  biomarkers th at inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the corr ect drug/vaccine at the cor rect time. The 
details of this future biomedical r esearch substudy  are presented in Appendix 6.
4.2.[ADDRESS_832300], and widespread use of licensed PCV sworldwide. 
Prevnar 13™ is currentl y the most widely recommended vaccine for the prevention of 
pneumococcal disease in infants in many  countries worldwide, includes the largest number of
seroty pes, and will be used as the active comparator in this study .
Refer to approved labeling for detailed background information on Prevnar 13™. 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  31
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
4.3 Justification for Dose
The dose and dosing schedule of V114 is similar to that used in previous pediatric V114 
clinical studies, which demonstrated safet y and comparable immune responses to those of 
Prevnar 13™. Refer to V114 IB for details on dosing schedule.
In order to support initial licensure in countries that use either t he 3+1 Prevnar 13™ dosing 
schedule (3 doses in the infant primary  series followed by 1 toddler dose) or the 2+1 
Prevnar 13™ dosing schedule (2 doses in infant primary  series followed by 1 toddler dose), 
this study  will use the currentl y approved dose and U nited States Advisory C ommittee on 
Immunization Practices recommended 3+1 dosing schedule of Prevnar 13™.
4.[ADDRESS_832301] to follow -up (ie, the participant is unable to 
be contact[INVESTIGATOR_530] b y the investigator).
For purposes of analy sis and reporting, the ove rall study  ends when the Sponsor receives the 
last laboratory result or at the time of final contact [CONTACT_26355], whichever comes 
last.
4.4.1 Clinical Criteria f orEarly Study Termination
The clinical stud y ma y be terminated earl y if the extent (in cidence and/or severit y) of 
emerging effects/clinical endpoints is such that the risk/benefit ratio to the study population 
as a whole is unacceptable. In addition, further recruitment in the study or at (a)particular 
study site(s) may  be stopped due to insufficient compliance with the protocol, Good Clinical 
Practice ( GCP ), and/or other applicable regulatory requirements, procedure -related problems 
or an unacceptabl y high number of discontinuations or withdrawals due to administrative 
reasons.
5STUDY POPULATION
Health ymale and female infants approximately  2 months of age, from 42 and 90 day s
(inclusive) will be enrolled in this study .
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.[ADDRESS_832302] :
1.Behealthy  (based on a review of medical history  and phy sical examination) based on the 
clinical judgement of the investigator. 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  32
PROTOCOL/AMENDMENT N O.:031-[ADDRESS_832303] be excluded from the study  if the participant:
Medical Conditions
1.Has a history  of IPD(positive blood culture, positive cerebrospi[INVESTIGATOR_63469], or other 
sterile site) or known history of other culture positive pneumococcal disease.
2.Has a known h ypersensitivity  to any  component of the PCV or an y diphtheria toxoid -
containing vaccine.
3.*Had a recent febrile illness (rectal temperature ≥38.1°C [≥100.5°F] or axillary  
temperature ≥37.8°C [≥100.0°F]) occurring within 72 hours prior to receipt of study  
vaccine.
4.Has a known or suspected impairment of immunological function.
5.Has a history  of congenital or acquired immunodeficiency .
6.Has or his/her mother has a documented human immunodeficiency  virus (HIV) infection.
7.Has known or history  of functional or anatomic asplenia.
8.Has failure to thrive based on the cli nical judgement of the investigator .
9.Has a known coagulation disorder contraindicating intramuscular vaccination.
10.Has a history  of autoimm une disease (including but not limited to sy stemic lupus 
erythematosus, antiphospholipid sy ndrome, Behcet’s disease, autoimmune thy roid 
disease, pol ymyositis and dermatomyositis, scleroderma, t ype 1 diabetes mellitus, or 
other autoimmune disorders). 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  33
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
11.Has a known neurologic or cognitive behavioral disorder, including encephalitis/my elitis, 
acute disseminating enc ephalomy elitis, pervasive development disorder, and related 
disorders.
Prior/Concomitant Therapy
12.Has received a dose of any  pneumococcal vaccine prior to study  entry .
13.*Meets one or more of the following s ystemic corticosteroid exclusion criteria:
a.Has recei ved s ystemic corticosteroids (equivalent of ≥2 mg/kg total dail y dose of 
prednisone or ≥20 mg/d ayfor persons weighing >10 kg) for ≥[ADDRESS_832304] of the study .
Note : Topi [INVESTIGATOR_2855], ophthalmic and inhaled steroids are permitted.
14.*Has received other licensed non- live vaccines within the [ADDRESS_832305] 
dose of study  vaccine.
15. *Has received a licensed live virus vaccine within the [ADDRESS_832306] dose of study  vaccine .
Prior/Concurrent Clinical Study Experience
17.Has participated in another clinical stud y of an investigational product before the 
beginning or anytime during the duration of the current clinical stud y. Participants 
enrolled in observational studies may  be included; t hese will be reviewed on a case -by-
case basis for approval by [CONTACT_1034].
Other Exclusions
18.Has an y other reason that, in the opi[INVESTIGATOR_871], may interfere with the 
evaluation required b y the study. Reasons may  include, but are not limited to, being 
unable to keep appointments or planning to relocate during the stud y.
19.Is or has an immediate family  member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study. 
  055BNR
055BNR
06DW3Y
PRODUCT: V114  34
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
For items with an asterisk (*), if the participant meets these exclusion criteria, Visit1
may be rescheduled for a time when these criteria are not met.
5.3 Lifestyle Considerations
No lifesty le restrictions are required.
5.4 Screen Failures
Screen failures are defined as participants whose legally acceptable representative provides 
consent to participate in the clinical study  but are not subsequently randomized in the study . 
A minimal set of screen failure information is required to ensure transparent reporting of 
screen failure participants to meet the Consolidated Standards of Reporting Trials
(CONSORT) publishing requirements and to respond to queries from regulatory authorities . 
Minimal information includes demograph y, screen failure details, eligibility criteria, and any 
AEs or SAEs meeting reporting requirements as outlined in the data entr y guidelines.
5.5 Participant Replacement Strategy
A participant who withdraws from the stud y will not be replaced.
6STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, or 
medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
Clinical supplie s (V114 and Prevnar 13™) will be packaged to support enrollment . Clinical 
supplies will be affixed with a clinical label in accordance with regulatory requ irement s.
6.1 Study Intervention(s) Administered
The study intervention (s) to be used in this study areoutlined inTable [ADDRESS_832307]: V114  35
PROTOCOL/AMENDMENT N O.:031-01 
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Table 1 Study  Intervention s
Arm 
NameArm TypeIntervention 
NameTypeDose 
FormulationUnit Dose 
Strength(s)Dosage 
Level(s)Route 
of 
Admin .Vaccination 
RegimenUseIMP/
NIMPSourcing
V114Experimental V114 Biological
/VaccineSterile 
SuspensionRefer to IB 0.5 mL IM Single dose at 
Visits 1, 2, 3, and 
5 (~2, 4, 6, and 12 
to 15 months of 
age, respectively)Experi
mentalIMP Central
Prevnar 
13™Active 
ComparatorPrevnar 13™ Biological
/VaccineSterile 
SuspensionRefer to 
product 
labeling0.5 mL IM Single dose at 
Visits 1, 2, 3, and 
5 (~2, 4, 6, and 12 
to 15 months of 
age, respectively)Experi
mentalIMP Central
Admin = administration; IB = Investigator’s Brochure; IM = intramuscular; IMP = investigational medicinal product; NIMP = non -investigational medicinal product
Definition Investigational Medicinal Product (IMP) and Non -Investigational Medicinal Product (NIMP) is based on guidance issued by [CONTACT_63512]. Regional 
and/or Country differences of the definition of IMP/NIMP may exist. In these circumstances, loc al legislation is followed. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  36
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
All supplies indicated in Table 1 will be provided per the "Sourcing" column depending upon 
local country  operational requirements. If local sourcing, e very attempt should be made to 
source these supplies from a single lot/ba tch number where possible (eg, not applicable in the 
case where multiple lots or batches may be required due to the length of the study, etc).
Refer to Section 8.1.8 for details regarding administration of the study  intervention.
6.2 Preparation/Handling/Stora ge/Accountability
6.2.[ADDRESS_832308] be stored 
in a secure, environmentally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsibl e for stud y intervention accountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all stud y sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that m ust be completed for drug accountability  and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study  site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_63470] y purchased product (if applicable) 
as per local guidelines unless otherwise 
instructed by  [CONTACT_1034].
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of stud y 
interventions in accordance with the protocol and any applicable laws and regulations. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  37
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
6.3 Measures to Minimize Bias: Ra ndomization and Blinding
6.3.1 Intervention Assignment
Intervention allocation/randomization will occur centrally  using an interactive response 
technology  (IRT) s ystem. There are 2study  intervention arms. Full-term infant participants 
(gestational age ≥37 weeks) will be assigned randomly  in a 5:1 ratio to receive V114 or 
Prevnar 13™. Premature infant participants (gestational age <37 weeks) in the 
immunogenicit y substudy will be assigned randomly in a 1:1 r atio to receive V114 or 
Prevnar 13™.
6.3.2 Stratification
Intervention allocation/randomization will be stratified according to the following factors:
Gestational age <37 weeks (yes/no)
6.3.3 Blinding
Adouble -blinding technique will be used. V114 and Prevnar 13™ willbe prepared and/or 
dispensed by  [CONTACT_63513]. The 
participant and the investigator who are involved in the clinical evaluation of the participants 
will remain blinded to the group assignments.
Because V114 and Prevnar 13™ have a different appearance, a member of the study site staff 
will be unblinded for the purpose sof receiving, maintaining, preparing ,and administering 
thesestudy vaccine s.Procedures for handling, preparing, and administering the u nblinded 
vaccines are located in the Investigator Trial File Binder.
In order to avoid bias, the unblinded study person nelwill have no further contact [CONTACT_252325] -related procedures/assessments after administration of study  
vacci nes, which includes all safety follow -up procedures . Additionall y, blinded site 
personnel will not be present in t he exam ination room when study  vaccines are administered. 
Contact [CONTACT_624754] .Blinded site personnel will be responsible for all safety  and 
immunogenicit y follow -up procedures after vaccine administration.
An unblinded Clinical Research Associate will monitor vaccine accountability  at the study  
site. All other Sponsor personnel or delegate(s) and [COMPANY_006] Research Laboratories emplo yees 
directly  involved with the conduct of this study  will remain blinded to the participant -level 
intervention assignment.
See Section 8.1.[ADDRESS_832309]:   V114  38
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
6.4 Study Intervention Compliance
Interruptions from the protocol -specified plan for V114 or Prevnar 13™ vaccinat ion
indicated in Sec tion1.3 require consultation between the investigator and the Sponsor and 
written documentation of the collaborative decision on participant management.
6.5 Concomitant Therapy
Medications or vaccinations specificall y prohibited in the exclusion criteria are not allo wed
during the ongoing stud y(see Section 5.2 for details) . If there is a clinical indication for an y 
medications or vaccinations specificall y prohibited, di scontinuation from study  intervention 
may be required. The investigator should discuss any  question s regarding this with the 
Sponsor Clinical Director . The final decision on any supportive therap y or vaccination rests 
with the investigator and/or the participant ’s primary  physician. However, the decision to 
continue the participant on study  intervention requires the mutual agreement of the 
investigator, the Sponsor, and the 
participant’s legally  acceptable representative .
If a medical condition requires the use of a prohibitive steroid regimen, immunoglobulin, 
blood, or blood products during a participan t's participation in this study , one of the 
individuals listed on the Sponsor Contact I nformation page must be notified as soon as 
possible. Any  concurrent medication or medical treatment must be recorded on the 
appropriate electronic Case Report Form ( eCRF). It is important to record the use of an y 
analgesic or antipy retic use that occurs on the day  of vaccination on the eVRC and 
appropriate eCRF.
During influenza season, it is anticipated that participants [ADDRESS_832310] be taken to prevent choking during the administration 
of oral vaccines. Other injectable vac cines should be given after the stud y vaccine .These 
vaccinations should be recorded on the appropriate eCRF.
V114 or Prevnar 13™ should be administered in the right thigh. To avoid any  confounding 
results, nonstudy  injectable vaccines should not be administered in the same limb as V114 or 
Prevnar 13™. Documentation of which limb was used for the administration of V114 or 
Prevnar 13™ should be recorded on the appropriate eCRF. As the stud y is reporting 
injecti on-site AEs for V114 or Prevnar 13™ (and not from the nonstudy  pediatric vaccines), 
this information should also be recorded on the eVRC to inform the parent or legally  
acceptable representative of the appropriate limb to m onitor for AEs related to the V114 or 
Prevnar 13™. 
No other investigational compound or device may be administered at an y time during this 
study  without prior approval by  [CONTACT_1034]. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  39
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
6.5.1 Rescue Medications and Supportive Care
No rescue or supportive medicati ons are specified for use in this study .
6.6 Dose Modification (Escalation/Titration/Other)
No dose modification is allowed in this study .
6.7 Intervention After the End of the Study
There is no stud y-specified intervention following the end of the stud y.
6.8 Clinical Supplies Disclosure
This study  is blinded but supplies are provided as open label ; therefore, an unblinded 
pharmacist or qualified study  site personnel will be used to blind supplies. Study  intervention
identity  (name, strength, or potency ) is included in the label text; random code/disclosure 
envelopes or lists are not provided.
The emergency  unblinding call center will use the intervention
/randomization schedule for 
the study  to unblind participants and to unmask study  intervention identity . The emergenc y 
unblinding call center should only  be used in cases of emergency  (see Section 8.1.13). In the 
event that the emergency unblinding call center is not available for a given site in this study , 
the central electronic intervention allocation/randomization sy stem (IRT) should be used to 
unblind participants and to unmask study  intervention identity . The Sponsor will not provide 
random code/disclosure envelopes or lists with the clinical supplies.
See Section 8.1.[ADDRESS_832311] be collected through the participant’s last scheduled follow -
up, even if the participant has discontinued study  intervention. Therefore, all participants 
who discontinue study  intervention prior to completion of the protocol -specified vaccination 
regimen will still continue to participate in the study  as specified in Section 1.3 and 
Section 8.12.3 unless the consent is withdrawn for the partici pant (Sec tion7.2).A participant 
may discontinue from study  intervention (including receipt of V114 or Prevnar 13™) but 
continue to participate in protocol -specified, AE- monitoring activities (see Section 8.12.3 for 
details). 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  40
PROTOCOL/AMENDMENT N O.: 031-[ADDRESS_832312] 
occur. In addition, a participant may  be discontinued from study  intervention by  [CONTACT_443157], the stud y plan is violated, or 
for administrative and/or other safet y reasons. Specific details regarding procedures to be 
performed at study  intervention discontinuation are provided in Section 8.1.[ADDRESS_832313] be discontinued from study intervention but continue to be monitored in 
the study  for an y of the following reasons:
•The participant or participant’s legall y acceptable representative requests to discontinue 
study  intervention.
•The part icipant’s treatment assignment isunblinded by  [CONTACT_624755].
•The participant has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_19348]/or Sponsor, places the participa nt at unnecessary  risk from continued 
administration of study intervention.
For participants who are discontinued from study  intervention but continue to be monitored 
in the study , see Section 1.3 and Section 8.12.3 for those procedures to be completed at each 
specified visit.
Discontinuation from study  intervention is “permanent.” Once a participant is discontinued, 
he/she shall not be allowed to restart stud y intervention .
7.[ADDRESS_832314] be withdrawn from the stud y if the participant or participant’s legall y 
acceptable representative withdraws consent from the study .
If a participant withdraws from the study, they will no longer receive stud y intervention or be 
followed at scheduled protocol visits.
Specific detail s regarding procedures to be performed at the time of withdrawal from the 
study ,as well as specific det
ails regarding withdrawal from future biomedical r esearch, are 
outlined in Section 8.1.12. The procedures to be performed should a participant repeatedl y 
fail to return for scheduled visits and/or if the study site is unable to contact [CONTACT_63517] 7.3. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  41
PROTOCOL/AMENDMENT N O.: 031-[ADDRESS_832315] t o Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is un able 
to contact [CONTACT_2299], the following procedures are to be performed:
•The site must attempt to contact [CONTACT_2299]’s legally  acceptable representative and 
reschedule the missed visit. I f the participant’s legally  acceptable representative is 
contact[INVESTIGATOR_530], the participant’s legally  acceptable representative should be counseled on the 
importance of maintaining the protocol -specified visit schedule .
•The investigator or designee must make every  effort to regain contact [CONTACT_151525]’s legall y acceptable representative at each missed visit (eg, telephone calls 
and/or a certified letter to the legally acceptable representative last known mailing 
address or locally  equivalent methods). These contact [CONTACT_62542]’ s medical record.
•Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and anal ysis guidel ines.
8STUDY ASSESSMENTS AND PROCEDURES
•Study  procedures and their timing are summarized in the SoA.
•Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
•The investigator is responsi ble for ensuring that procedures are conducted by  
[CONTACT_11399] y qualified or trained staff. Delegation of study site personnel responsibilities 
will be docu
mented in the Investigator Trial File Binder (or equivalent).
•All study -related medica l decisions must be made by  [CONTACT_19427] a qualified 
physician .
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of ICF may  be utilized for screening or baseline 
purposes provided the procedure met the protocol -specified criteria and were performed 
within the time frame defined in the SoA. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  42
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
•Additional evaluations/testing may  be deemed necessary  by [CONTACT_624756] y. In some cases, such evaluation/testing 
may be potentially  sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. I n these 
cases, such evaluations/testing will be performed in accordance with those regulations.
For participants in the Premature Infant Immunogenicity  Substudy only, approxi mately  5 mL
ofblood will be drawn at the visits indicated in Section 1.3. The maximum amoun t of blood 
collected from each participant over the duration of the study  during planned study  visits will 
not exceed 15 mL. 
Repeat or unscheduled samples may  be taken for safet y reasons or for technical issues w ith 
the samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or 
medically  qualified designee (consistent with local requirements) must 
obtain documented consent from each potential participant or each participant’s legall y 
acceptable representative prior to participating in a clinical study or future biomedical 
research .If there are changes to the participant’s status during the stud y (eg, health or age of 
majority  requirements), the investigator or medically  qualified designee must ensure the 
appropriate consent is in place.
[IP_ADDRESS] General Informed Consent
Consent must be documented by  [CONTACT_2299]’s dated signature [INVESTIGATOR_1660] b y the participant’s 
legally  acceptable representative’s dated signature [INVESTIGATOR_2394] a consent form along with the dated 
signature [CONTACT_63564].
A copy of the signed and dated consent form should be given to the participant’s legall y 
acceptable representative before the individual’s participation in the study .
The initial I CF, any  subsequent revised written ICF and an y written informat ion provided to 
the participant’s legally  acceptable representative must receive the Institutional Review 
Board/Independent Ethics Committee’s (I RB/IEC’s) approval/favorable opi[INVESTIGATOR_105908]. The participant’s legally  acceptable representative sho uld be informed in a timely  
manner if new information becomes available that may  be relevant to the willingness for the 
participant to continue participation in the study. The communication of this information will 
be provided and documented via a revised consent form or addendum to the original consent 
form that captures the dated signature [CONTACT_77525]’s legall y acceptable representative .
Specifics about a stud y and the study population will be added to the consent form template 
at the protocol leve l. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  43
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, 
and Sponsor requirements .
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically  qualified designee will explain the fut ure biomedical research 
consent to the participant’s legally acceptable representative, answer all of his/her questions, 
and obtain written informed consent before performing an y procedure related to the future 
biomedical research substudy . A cop y of the i nformed consent will be given to the 
participant’s legall y acceptable representative .
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_093] ,who is a qualified 
physician ,to ensure that the participant quali fies for the study .The investigator should 
consult with the Sponsor’s Clinical Director for any  questions about participant eligibility .
If the participant meets any  of the e xclusion criteria with an asterisk (*), Visit [ADDRESS_832316] information (including direct telephone numbers) to be utilized 
in the event of an emergency . The investigator or qualified designee will provide the legall y 
acceptable representative for each participant with a Participant Identificatio n Card 
immediately  after written informed consent is provided. At the time of treatment 
allocation/randomization, site personnel will add the treatment/randomization number to the 
Participant Identification Card.
The participant identification card also co ntains contact [CONTACT_75345] a healthcare provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.4 Medical History
A medical history  will be obtained by  [CONTACT_63524] 1. Note: birth weight (kg) and gestational age will be documented in the 
participant’s medical history . 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  44
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
8.1.5 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
The investigat or or qualified designee will review and record prior vaccinations and 
medications taken b y the participant within [ADDRESS_832317] dose of study vaccine at 
Visit 1.
[IP_ADDRESS] Concomitant Medications
The investigator or qualified designee will record medication, if an y, taken by [CONTACT_63525] y.
If a medical condition requires the use of a prohibitive steroid regimen , immunoglobulin, 
blood, or blood products during a participant’s participation in this study , one of the 
individuals listed on the Sponsor Contact I nformation page must be notified as soon as 
possible. Any  concurrent medication or medical treatment must be recorded on the 
appropriate eCRF. 
It is important to record any  analgesic or antipy retic use that occurs on the day  of vacci nation 
on the eVRC and appropriate eCRF. Concomitant medications taken after Visit 1 and 
nonstudy  vaccines received since Visit 1 will be recorded with the eVRC as specified in 
Section 8.3.3.
Nonstudy  pediatric vaccines administered during the study should be recorded on the 
appropriate eCRF. Injectable vaccines should not be administered in the same limb as V114 
or Prevnar 13™. Documentation of which limb was used for the administration of V114 or 
Prevnar 13™ must be recorded on the eVRC (Section 8.3.3) and appropriate eCRF. 
8.1.[ADDRESS_832318] not be re -used for 
different participants.
Any participant who is screened multiple times will retain the original screening number 
assigned at the initial screening visit. Specific details on the screening/rescreening visit 
requirements are provided in Section 8.12.1.
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible participants will be randomly allocated and will receive a 
treatment /randomization number. The treatment /randomization number identifies the 
participant for all procedures occurring after 
treatment allocation/randomization. Once a 
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  45
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
A single participant cannot be assign ed more than 1 treatment /randomization number.
8.1.[ADDRESS_832319] of the study  will prepare 
and administer the study  vaccine. Study  vaccines should be prepared and administered by  
[CONTACT_11399] y qualified members of the stud y personnel ( eg, physician, nurse, physician’s 
assistant, nurse practitioner, pharmacist or medical assistant) as allowed b y local/ state, 
country  and institutional guidance. Procedures for handling, preparing, and administering the 
unblinded vaccines are provided in the Investigator Trial File Binder. Unblinded study  
personnel should follow the preparation and administration instructions for Prevnar 13™ as
specified in the product label.
Study  vaccines should be removed from the refrigerator no more than 1 hour before 
vaccination. The time of removal and time of vaccination should be documented in the 
participant’s chart.
If the V114 is provided as a sy ringe : Prior to administration of study  vaccine, the unblinde d 
pharmacist should shake vigorousl y to obtain a homogenous white suspension. If 
white -colored insoluble particle appears, the unblinded pharmacist should use rapid, 
horizontal hand- shaking for 5 to 10 seconds while holding the s yringe in be tween the thumb
and index finger until complete resuspension. This action should be repeated, as necessary. If 
appearance is otherwise, the vaccine should not be administered. 
If V114 is provided as a vial : Prior to administration of study vaccine, the unblinded 
pharmacist should use rapid, horizontal hand -shaking for up to 5 seconds while holding the 
vialin between the thumb and index finger to obtain a homogenous white suspension. This 
action should be re peated, as necessary . If appearance is otherwise, the vac cine should not be 
administered. 
The vaccine should not be used if the vaccine cannot be resuspended.
A 0.5 -mL intramuscular dose of study  vaccine will be administered to healthy infants at 
approximately  2, 4, 6, and 12 to 15 months of age. Prevnar 13™ will be supplied as a 
pre-filled s yringe. The study  vaccines are to be administered at the locations recommended in 
Section 6.5. If an abnormality  (ie, rash) is observed at the site where the previous dose of the 
study  vaccine was administered, it is permiss ible to use the anterolateral muscle of the other 
limb to administer the following dose of the study  vaccine. Adequate treatment provision, 
including epi[INVESTIGATOR_93271], should be available for 
immediate use should an anaph ylactic or anaph ylactoid reaction occur [Centers for Disease 
Control and Prevention 2015] .
Unblinded study  personnel should not have contact [CONTACT_624757] y-related 
procedures/assessments after a dministration of study  vaccines, which includes all safet y 
follow -up procedures. All safet y and immunogenicity assessments will be conducted b y 
blinded personnel, and the participant or participant’s parent/guardian will be blinded to the 
study  vaccine rec eived by  [CONTACT_2299]. Vaccination information, such as Component  
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  46
PROTOCOL/AMENDMENT N O.: 031-[ADDRESS_832320] be recorded on the appropriate eCRF as 
per the Data Entry Guidelines.
[IP_ADDRESS] Timing of Dose Administration
V114 or Prevnar 13™ will be administered as indicated in Section 1.3. All participants will 
be observed for [ADDRESS_832321] be performed by [CONTACT_252332] V114 and Prevnar 13™ 
(Section 1.3 and Section 6.3.3).
Participants must be afebrile for at least [ADDRESS_832322]
The eVRC was developed to be administered electronically  via a hand -held device. This item 
was structured as recommended in the final Food and Drug Administration Patient Reported 
Outcome Guidance [U.S. Food and Drug Administration 2009] . The investigator or delegate 
will train the participant’s legall y acceptable representative in the use of the eVRC as 
indicated in Section 1.3.
Body temperatures, injection -site reactions, vaccine -specific complaints, other complaints o r 
illnesses, and concomitant medications or nonstudy  vaccinations will be recorded on the 
eVRC as described in Section 1.3 and Section 8.3.3. The investigator or delegate will review 
the data captured on the eVRC with the participant’s legally  acceptable r epresentative as 
indicated in Section 1.3.
For the AEs outlined above, the investigator will use the information provided by [CONTACT_2416]’s legall y acceptable representative both on the eVRC, and verbally  at the time of 
eVRC review, to appl y the appropr iate assessment of intensity  as described in Appendix 3.
8.1.[ADDRESS_832323] each dose to review eVRC data 
with the participant’s legally  acceptable representative. The Day  [ADDRESS_832324] an y updates or edits to data previously  entered on the eVRC from the 
participant’s legall y acceptable representative . Any differences between eVRC data and the 
clinical database must be clearl y explained in the participant’s source documentation with an 
indication of where the information was obtained (eg, from the Day  [ADDRESS_832325] with the participant’s l egall y acceptable representative ). 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  47
PROTOCOL/AMENDMENT N O.: 031-[ADDRESS_832326] the participant’s legally acceptable representative approximately  
6months after the last dose of study  vaccine to collect additional information based on a 
Telephone Contact [CONTACT_624758]. Data to be reported from this 
discussion will include SAEs and/or any updates to previously reported safety information.
8.1.12 Discontinuation and Withdrawal
Participants who discontinue study  intervention prior to completion of the p rotocol- specified 
vaccinations should be encouraged to continue to be followed for all remaining stud y visits
as outlined in the Section 1.3and Section 8.12.3.
When a participant withdraws from participation in the study, all applicable activities 
scheduled for the final study  visit (Visit 6) should be performed (at the time of withdrawal). 
Any AEs that are present at the time of withdrawal should be followed in accordance with 
the safet y requirements outlined in Section 8.4.
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Consent for future biomedical research may  be withdrawn b y the participant’s legally 
acceptable representative. Consent may  be withdrawn b y the legall y acceptable 
representative at an y time by  [CONTACT_624759] . If 
medical records for the main study  are still available, the investigator will contact [CONTACT_63527] ([EMAIL_1250]). 
Subsequently , the participant's consent for fu ture biomedical research will be withdrawn. A 
letter will be sent from the Sponsor to the investigator confirming the withdrawal. It is the 
responsibility  of the investigator to inform the participant’s legally  acceptable representative 
of completion of wi thdrawal. An y anal yses in progress at the time of request for withdrawal 
or alread y performed prior to the request being received b y the Sponsor will continue to be 
used as part of the overall research stud y data and results. No new analys es would be 
gener ated after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study records) 
or the specimens have been compl etely anon ymized, there will no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed.
8.1.13 Participant Blinding/Unblindi ng
STUDY INTERVENT ION IDENT IFICATION INFORMATION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency  situations where the investigator or medically  qualified designee (consistent 
with local requirements) needs to identify  the intervention used by  a participant and /orthe  
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  48
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
dosage administered , he/she will contact [CONTACT_126537] a request for emergency  unblinding. As requested b y the investigator or medically  
qualified desi gnee, the emergency  unblinding call center will provide the information to 
him/her promptly  and report unblinding to the Sponsor. Prior to contact[CONTACT_126538] a participant’s intervention assignment, the
investigator who is a qualified phy sician should make reasonable attempts to enter the 
intensity of the AEs observed, the relation to study  intervention, the reason thereof , etc., in 
the medical chart. If it is not possible to record this assessment in the chart prior to the 
unblinding, the unblinding should not be delayed.
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason, and person performing the unblinding) must be documented promptly, and the 
Sponsor Clinical Director notified as soon as possible.
Once an emergency  unblinding that is part of the study  design has taken place, the principal 
investigator, site personnel, and Sponsor personnel may be unblinded so that the appropriate 
follow -up medical care can be provided to the participant.
Participants whose trea tment assignment has been unblinded by  [CONTACT_2697] y 
qualified designee and/or nonstudy  treating ph ysician must be discontinued from study  
intervention, but should continue to be m onitored in the study .
Additionally , the investigator or medically  qualified designee must go into the I RT sy stem 
and perform the unblind in the I RT sy stem to update drug disposition. In the event that the 
emergency  unblinding call center is not available for a given site in this study , the IRT 
system should be used for emergency  unblinding in the event that this is required for 
participant safety .
8.1.14 Calibration of Equipme nt
The investigator or qualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinica l study  that provides information 
about inclusion/exclusion criteria and/or safety or efficacy  parameters shall be suitably  
calibrat ed and /ormaintained to ensure that the data obtained is reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study  site.
8.2 Immunogenicity Assessmen ts
Two immunogenicit y assays (PnECL  and MOPA) will be used to measure vaccine- induced, 
anti-PnPs seroty pe-specific immune responses for all 15 serotypes included in V114 in the 
Premature Infant Immunogenicity  Substudy . 
Blood collection, storage and shipment instructions for serum samples will be prov ided in the 
operations/laboratory  manual. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  49
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
8.2.1 Pneumococcal Electrochemiluminescence
The Sponsor has developed and optimized a multiplex, electrochemiluminescence 
(ECL )-based detection method for the quantitation of IgG serot ype-specific antibodies to the 
15 Pn Ps seroty pescontained in V114. The PnECL v2.0 assay  is based on the Meso -Scale 
Discovery  technology , which employ s disposable multi- spot microtiter plates. The benefits 
of the ECL  multiplex technology  over the prior enzyme-linked immunosorbent assay
(ELISA) methodology  include speed, equivalent or better sensitivity , increased dy namic 
range, the ability  to multiplex, and reduction in required ser um sample and reagent volumes. 
The measurement of immune responses to the [ADDRESS_832327] IPD conferred b y 
the 7 conjugated pol ysaccharides in Prevnar™. In 2012 and 2014, the Sponsor formall y 
bridged the original PnECL  assay  to the WHO IgG ELI SA in order to determine the PnECL  
threshold values that correspond to 0.35 µg/mL  in the WHO ELIS A for each of the 7 
Prevnar™ seroty pes (4, 6B, 9V, 14, 18C, 19F, and 23F) and for each of the additional 6 
seroty pes (1, 3, 5, 6A, 7F, and 19A) in Prevnar 13™.
A confirmatory  study  was performed to formall y bridge the optimized PnECL  assay  (v2.0) to 
the WH O reference ELISA, and to assess the PnECL  threshold values that correspond to 
0.35 µg/mL  measured using the WHO ELISA for each of the serot ypes in V114, including 
the Prevnar 13™ serot ypes and serot ypes 22F and 33F, which were not previously  assessed. 
Thebridging of the optimized PnECL  to the WHO ELI SA is complete, and the data showed 
good concordance between the PnECL  and WHO ELISA around the 0.35 μg/mL th reshold 
value for all 15 serot ypes. I t is recommended that a single PnECL threshold value of 
0.35 µg/mL be applied to each of the 15 serot ypes.
8.2.2 Multiplex Opsonophagocytic Assay
The MOPA, developed and published by  [CONTACT_63532] (Director of the United 
States World Health Organization pneumococcal serology reference laboratory and National 
Institutes of Health pneumococcal reference laboratories), is a multiplexed OPA assay 
capable of measuring [ADDRESS_832328] a to tal of 16 serot ypes of pneumococci 
[Burton, Robert L . and Nahm, Moon H. 2006] . The OPA is an antibod y-mediated killing 
assay  that measures the ability of human serum to kill S. pneumoniae serot ypes with the help
of complement and phagocytic effector cells. The ability  of the assay  to simultaneously  test 
4seroty pes/run reduces the amount of serum needed for testing. The assay  readout is the 
opsonization index, which is the reciprocal of the highest dilution that gives ≥50% bacterial  
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  50
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
killing, as determined b y comparison to assay  background controls. The Sponsor has 
developed and optimized the MOPA in a high throughput micro -colon y platform. The 
MOPA assay  for all 15 V114 seroty pes has undergone validation. The vali dation study  
evaluated various performance parameters of the assay  including precision, relative 
accuracy /dilutional linearity , and specificit y. The validation results were evaluated against 
pre-specified acceptance criteria for each of the parameters.
8.3 Safety Assessments
Details regarding specific safet y procedures/assessments to be performed in this study  are 
provided below . The total amount of blood/tissue to be drawn/collected over the course of 
the study  (from prestud y to poststudy  visits), including ap proximate blood/tissue volumes 
drawn/collected by [CONTACT_126541], can be found in Section 8.
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete ph ysical examination will be per formed at Visit 1. A targeted phy sical 
examination will be performed at subsequent vaccination visits (Visits 2, 3, and 5). An y 
clinically  significant abnormality  will be recorded on the appropriate eCRF.
The full and targeted physical examination procedur es both include obtaining vital signs 
(heart rate, respi[INVESTIGATOR_2842], and rectal temperature), auscultation of the heart and lung, and 
examination of the abdomen. I n addition, a full phy sical examination will include an 
assessment of the head, eyes, ears, n ose and throat, skin, ly mph nodes, neurological sys tem, 
and musculoskeletal s ystem.
Findings related to the physical examinations should be documented in the participant’s 
chart/source documentation.
8.3.[ADDRESS_832329] febrile illness (rectal temperature ≥38.1°C [≥100.5°F] or axillary  
temperature ≥37.8°C [≥100.0°F]) occurring at or within [ADDRESS_832330] 
be rescheduled. Rectal is the preferred method of obtaining participant’s temperature. 
Axillary  (underarm) is an acceptable method but temperature needs to be confirmed by  [CONTACT_252339]. If an axillary  tempera ture is reported to be ≥37.8°C 
(≥100.0°F), a rectal temperature must be taken. In this case, both axillary  and rectal 
temperatures must be recorded on the eVRC. Temperature readings should be taken at 
approximately  the same time each day . Use of temporal o r tympanic thermometers to collect 
temperature for this study is prohibited.
The participant’s legally  acceptable representative will be asked to record the participant’s
temperature reading on the eVRC from Day [ADDRESS_832331]:   V114  51
PROTOCOL/AMENDMENT N O.: 031-[ADDRESS_832332] be recorded on the appropriate eCRF.
Participant’s legall y acceptable representative will use the eVRC (Section 8.1.9) to document 
the following information:
•Rectal temperatures measured Day 1 (day of vaccination) through Day 7 following e ach 
vaccination; Day 8 through Day 14 following each vacc ination if fever is suspected
•Solicited injection -site AEs ( swelling, redness, pain or tenderness , and hard lump) Day 1 
through Day 14 postvaccination
•Solicited sy stemic AEs ( irritability , drowsiness, appetite lost, and hives or welts ) Day 1 
through Day 14postvaccination
•Any other unsolicited injection -site or s ystemic AEs Day 1 through Day 14 
postvaccination
•The limb that was used for the administration of V114 or Prevnar 13™ ( Note: the study  
will report injection -site AEs from V114 or Prevnar 13™ and not from concomitant 
injectable vaccines; the location of V114 or Prevnar 13™ administration can be used b y 
the participant’s legally  acceptable representative to monitor the appropriate limb for 
injection- site AEs related to V114 or Prevnar 13™)
•Use of an y analgesic or antipy retic on the day of vaccination
•Concomitant medications and nonstudy  vaccinations Day 1 to Day 14 postvaccination
8.3.4 Clinical Safety Laboratory Assessments
There are no laboratory  safet y evaluations required by [CONTACT_760].
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs)
,and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causalit y of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safet y event reports can be found in Appendix 3. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  52
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Adverse events, SAEs, and other reportable safety events will be reported by  [CONTACT_2299] 
(or, when appropriate, b y a caregiver, surrogate, or the participant's legall y authorized 
represe ntative).
The investigator and an y designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safet y events. 
Investigators remain responsible for following up AEs , SAEs, a nd other reportable safety  
events for outcome according to Section 8.4.3.
The investigator, who is a qualified ph ysician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safet y events with respect to seriousness, 
intensity /toxicity  and causality .
8.4.1 Time Period and Frequency for Collecting AE, SAE ,and Other Reportable 
Safety Event Information
All AEs, SAEs, and other reportable safety events that occur after the consent form is signed 
but before allocation/randomization must be reported by [CONTACT_252340] , or are the result of a protocol -specified 
intervention, including but not limited to washout or discontinuation of usual therap y, diet, 
placebo treatment, or a procedure.
All AEs, SAEs, and other reportable safety events must be reported b y the investigator from 
the day  of allocation/randomization to the first vaccination and from the day of each 
vaccination through [ADDRESS_832333] also be r eported throughout the 
duration of the individual’s participation in the study, regardless of whether or not related to 
the Sponsor’s product.
Additionally , any SAE brought to the attention of an investigator at an y time outside of the 
time period specifie d in the previous paragraph also must be reported immediatel y to the 
Sponsor if the event is either :
a.A death that occurs prior to the participant completing the study.
OR
b.An SAE that is considered by [CONTACT_19427] a qu alified ph ysician to be 
vacci ne-related.
Investigators are not obligated to activel y seek AE sor SAEs or other reportable safety  events 
in former stud y participants. However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonabl y related to the study intervention or study  participation, 
the investigator must promptly  notify  the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety  events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table [ADDRESS_832334]:   V114  53
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Table 2 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safet y Events
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation through 
Protocol -specified 
Follow -up PeriodReporting Time 
Period:
After the Protocol -
specified Follow -up 
PeriodTime Frame 
to Report
Event and 
Follow -up 
Inform ation 
to Sponsor:
Nonserious Adverse 
Event (NSAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other run -
in treatmentReport all Not required Per data entry 
guidelines
Serious Adverse 
Event (SAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other run -
in treatmentReport all Report if:
-drug/vaccine related.
-any death until 
participant completion 
of study
(Follow  ongoing to 
outcome)Within 24 
hours of 
learning of 
event
Pregnancy/Lactation 
ExposureNot applicable since participants are infants.
Event of Clinical 
Interest There are no ECI sfor this study . Not 
applicable
Cancer Report if:
-due to 
intervention
-causes exclusionReport all Not required Within 5 
calendar days 
of learning of 
event
Overdose Report if:
-receiving placebo 
run-in or other run -
in medication Report all Not required Within 5 
calendar days 
of learning of 
event
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safet y events. Open -ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safet y events 
including pregnancy  and exposure during breastfeeding, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the  
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  54
PROTOCOL/AMENDMENT N O.: 031-[ADDRESS_832335] to follow -up (as defined in Section 7.3). In addition, the investigator will 
make every  attempt to follow all nonserious AEs that occur in randomized participants for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  [CONTACT_624760] r esponsibilities towards the safet y of participants and the 
safety of a stud y intervention under clinical investigation are met.
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the saf ety of a stud y intervention under clinical investigation. The 
Sponsor will comply  wth country -specific regulatory  requirements and global laws and 
regulations relating to safety reporting to regulatory authorities , IRB/IECs, and investigators.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R s) according to local regulatory  requirements and Sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify  the IRB/IEC, if appropriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeedi ng
Information in this section is not applicable since participants are infants.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as AEs 
or SAEs
This is not applicable to this study .
8.4.[ADDRESS_832336] (ECI s)
There are no events of clinical interest in this study.
8.[ADDRESS_832337]:   V114  55
PROTOCOL/AMENDMENT N O.: 031-[ADDRESS_832338] be reported b y the investigator wi thin 5 calendar day sto the 
Sponsor either by [CONTACT_26365]. Electronic reporting procedures can be found in 
the EDC data entry  guidelines. Paper reporting procedures can be found in the Investigator 
Trial File Binder (or equivalent).
8.6 Pharmacok inetics
PK parameters will not be evaluated in this study .
8.7 Pharmacodynamics
Pharmacod ynamic parameters will not be evaluated in this study .
8.8 Future Biomedical Research Sample Collection
If the participant’s legally  acceptable representative signs the future biomedical r esearch 
consent, the following specime ns will be obtained as part of future biomedical r esearch:
•Buccal swab DNA for future research
•Leftover stud y serum at the central laboratory  stored for future research after aliquoting 
samples for complet ion of immunogenicit y
8.9 Planned Genetic Analysis Sample Collection
Planned genetic a nalysis samples will not be evaluated in this study .
8.10 Biomarkers
Biomarkers are not evaluated in this study .
8.11 Medical Resource Utilization and Health Economics
Medical Resource Utilization and Health Economics are not evaluated in this study .
8.12 Visit Requirements
Visit requirements are outlined in Section 1.3.Specific procedure -related details are provided 
in Section 8.
8.12.1 Screening
Screening procedures will be conducted at Visit 1 
as outlined in Section 1.3.
8.12.2 Treatment Period/Vaccination Visit
Requirements during the treatment period are outlined in Section 1.3. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  56
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
If the participant develops a new clinical condition during the stud y that makes him/her 
ineligible for the study , the inve stigator should discuss with the Sponsor Clinical Director as 
soon as possible. The decision to continue the participant on study intervention requires the 
mutual agreement of the investigator, the Sponsor, and the participant’s legally acceptable 
represen tative.
8.12.3 Discontinued Participants Continuing to be Monitored in the Study
A participant may  discontinue from study  intervention (including receipt of V114 or
Prevnar 13™) but continue to participate in protocol -specified, AE- monitoring activities as 
outlined in Section 1.3, as long as the participant’s legally acceptable representative does not 
withdraw consent. Blood draws for immunogenicity  testing in the Premature Infant 
Immunogenicit y Substudy  could occur if agreed to by  [CONTACT_2299]’s legally  accep table 
representative at the discretion of the investigator.
9STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the study. Changes to 
analyses made after the protocol has been finalized, but prior to unblinding, will be 
documented in a supplemental SAP (sSAP) and referenced in the Clinical Study  Report for 
the study . Post hoc exploratory  analy ses will be clearl y identified in the Clinical Study 
Report .
9.1 Statistical Analysis Plan Summary
Key elements of the statistical anal ysis plan are summarized below; the comprehens ive plan 
is provided in Section 9.2 to Section 9.12.
Study Design Overview A Phase 3, Multicenter, Randomized, Double -blind, Active 
Com parator -controlled Study to Evaluate the Safety and T olerability 
of V114 in Healthy Infants (PNEU -LINK)
Treatm entAssignment Approximately 2400 healthy infants approximately 2 months of age
will be enrolled.
Full-term infants (gestational age ≥37 w eeks)will be randomly 
assigned in a 5:1 ratio to a complete dosing schedule of V114 or 
Prevnar 13™. 
Premature infants (gestational age <37 w eeks) will be randomly 
assigned in a 1:1 ratio to a complete dosing schedule of V114 or 
Prevnar 13™
Analysis Populatio ns Safety: All Participants as Treated (APaT)
Immunogenicity: Per -Protocol (PP) and Full Analysis Set (FAS) 
population for the Premature Infant Immunogenicity Substudy 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  57
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Prim ary Endpoint(s) Proportion of participants with solicited injection -site AEs 
(swelling, redness /erythema ,tenderness /pain, and hard 
lump /induration ) from Day 1 through Day 14 following any 
vaccination with V114 or Prevnar 13™
Proportion of participants with solicited systemic AEs ( irritability, 
drowsiness /somnolence, appetite los t/decreased appetite , and 
hives or welts/urticaria ) from Day 1 through Day 14 following any 
vaccination with V114 or Prevnar 13™
Proportion of participants with vaccine -related SAEs from Day 1 
through completion of study participation
Key Secondary Endpoint s Premature Infant Immunogenicity Substudy only:
Anti-pneumococcal polysaccharide ( PnPs )serotype -specific 
Immunoglobulin G ( IgG) Geometric Mean Concentrations 
(GMCs )for the 15 serotypes contained in V114 at 30 days 
PD3, prior to Dose 4 and at 30 days PD4
Anti-PnPs serotype -specific IgG response rates (proportion of 
participants meeting serotype -specific IgG threshold value of 
≥0.35 μg/mL) for the 15 serotypes contained in V114 at 30 
days PD3 
Statistical Methods for Key 
Efficacy/Immunogenicity/ 
Pharm acokinetic AnalysesImmunogenicity analyses will be conducted for each of the 15 
pneumococcal serotypes contained in V114 separately. To address the 
immunogenicity objective s, evaluation of the IgG GMCs and a nti-PnPs 
serotype -specific IgG response rat es will be summarized descriptive ly.
Statistical Methods for Key 
Safety AnalysesP-values (Tier 1 endpoints) and 95% CIs (Tier 1 and Tier 2 endpoints) 
will be provided for betw een-vaccination group differences in the 
percentage of participants with events; these analyses will be 
performed using the M&N method [Miettinen, O. and Nurminen, M. 
1985] .
Interim Analyses To support the periodic review of safety and tolerability data across the    
V114 Phase [ADDRESS_832339] to enable a 
benefit -risk assess ment.
Multiplicity No m ultiplicity adjustment is planned .
Sample Size and Power Immunogenicity :
The immunogenicity objectives for this study are descriptive 
secondary objectives for the Prem ature Infant Immunogenicity 
Substudy only. The study will rand omize premature infant participants 
in a 1:1 ratio to either V114 or Prevnar 13™ vaccination group. The 
sample size of the Prem ature Infant Immunogenicity Substudy will be 
approximately 1% to 2% of overall participants .There is no hypothesis 
to be evaluated for immunogenicity objectives. Section 9.9.1 provides 
information about the expected variability of the IgG GMC given the 
sample size.
Safety:
Section 9.9.[ADDRESS_832340]:   V114  58
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
9.2 Responsibility for Analyses/In -house Blinding
The statistical anal ysis of the data obtained from this study  will be the responsibility  of the 
Clinical Biostatistics department of th e Sponsor .
This study  will be conducted as a double -blind study  under in -house blinding procedures. 
The official, final database will not be unblinded until medical/scientific review has been 
performed, protocol deviations have been identified, and data ha ve been declared final and 
complete.
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
study  intervention assignment . Randomization will be implemented in an IRT.
Blinding issues related to the planned interim an alyses are described in Section 9.7 . 
9.3 Hypotheses/Estimation
Objectives of the stud y are stated in Section 3. There is no h ypothesis to be evaluated in this 
study . 
9.4 Analysis Endpoints
Safety  endpoints for all participants and immunogenicity  endpoints for the Premature Infant 
Immunogenicit y Substudy that will be evaluated for within- and/or between -treatment 
differences are listed below.
9.4.1 Immunogenicity Endpoints
The immunogenicit y analy ses are for the Premature Infant Immunogenicity  Substudy  only. 
A description of immunogenicity  assessments for the Premature Infant Immunogenicit y 
Substudy  is contained in Section 8.2. I mmune responses will be measured for the 15 
seroty pes contained in V114 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and
33F).
The secondary immunogenicity  anal ysis endpoint sinclude:
Anti-PnPs seroty pe-specific Immunoglobulin G ( IgG)Geometric Mean 
Concentrations ( GMCs
)for the 15 serot ypes contained in V114 at 30 days PD3, prior 
to Dose 4 and at 30 day s PD4
Anti-PnPs ser otype-specific IgG response rates (proportion of participants meeting 
seroty pe-specific IgG threshold value of ≥0.35 μg/mL) for the 15 seroty pes contained 
in V114 at 30 day s PD3
The exploratory  immunogenicity  anal ysis endpoint include s:
Anti-PnPs seroty pe-specific OPA GMTs for the [ADDRESS_832341]:   V114  59
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
9.4.2 Safety Endpoints
A description of safet y measures is contained in Sections 8.3 and 8.4. The anal ysis of safety  
results is described in Section 9.6.2.
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters including 
adverse event s and postvaccination temperature measurements following any  vaccination 
with V114 or Prevnar 13™.
The safet y analysis endpoints include:
Proportion of participants with solicited injection- site AEs (swelling, 
redness/ery thema, tenderness/pain, and hard lump/induration) from Day 1 through 
Day 14 following an y vaccination with V114 or Prevnar 13™
Proportion of participants with solicited sy stemic AEs (irritability , 
drowsiness/somnolence, hives or welts /urticaria , and appetite loss/ decreased appetite ) 
from Day 1 through Day 14 following an y vaccination with V114 or Prevnar 13™
Proportions of participants with the broad AE categories consisting of any AE, a 
vaccine -related AE, an SAE, an AE which is both vaccine -related and serious, and 
discontinuation due to an AE, and the proportion of participants who died
Participant s body  temperature measured Day 1 (day of vaccination) through Day 7 
following a ny vaccin ation with V114 or Prevnar 13™
9.5 Analysis Populations
9.5.1 Immunogenicity Analysis Populations
The immunogenicit y analy ses will be performed for the Premature Infant Immunogenicit y 
Substudy  only.The Per-Protocol ( PP)population will serve as the primary population for the 
analysis of immunogenicity  data in this study . The PP population consists of all randomized 
participants in the Premature Infant I mmunogenicity  Substudy without deviations from the 
protocol that may  substantially  affect the results of t he immunogenicit y endpoint(s). Potential 
deviations that may  result in the exclusion of a participant from the PP population for all 
immunogenicit y anal yses include:
Failure to receive primary infant series vaccination (V11 4 or Prevnar 13™ Doses 1, 
2, and 3) as per randomization schedule
Receipt of prohibited medication or prohibited vaccine prior to stud y vaccination 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  60
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Additional potential deviations that may  result in the exclusion of a participant from the PP
population for specific immunogenicit y analys es (depending on the time point for anal ysis) 
include:
Failure to receive study vaccine (V114, Prevnar 13™) according to vaccination 
schedule required at the time point for the anal ysis
Failure to receive the scheduled doses of V114 or Prevnar 13™ (at least 28 day s 
between Doses 1 and 2 and between Doses 2 and 3 [for PD3 and pre -dose 4 anal ysis], 
12 months to 1 day  prior to 16 months of age for Dose 4 [for PD4 PP analy ses])
Receipt of prohibited medication or prohibited vaccine prior to a blood samp le 
collection
Collection of blood sample at the time point for the anal ysis outside of the 
pre-specified window (as described in Section 1.3)
The final determination on protocol deviations, and thereb y the composition of the PP
population, will be made pri or to the final unblinding of the database. Participants will be 
included in the vaccination group to which they  are randomized for the analy sis of 
immunogenicit y data using the PP population.
A supportive anal ysis using the Full Anal ysis Set ( FAS)populat ion will also be performed 
for the immunogenicity  endpoints. The FAS population consists of all randomized 
participants who received all study  vaccinations required at the time point for the analy sis 
and have serology  result. Participants will be included in the vaccination group to which they  
are randomized for the analy sis of immunogenicity  data using the FAS population.
9.5.2 Safety Analysis Populations
Safety  analyses will be conducted in the All Participants as Treated ( APaT )population, 
which consists of al l randomized participants who received at least one dose of study  
vaccination. Participants will be included in the group corresponding to the study vaccination 
they actuall y received for the anal ysis of safety  data using the APaT population. This will be 
the group to which they  are randomized except for participants who take incorrect study 
vaccination; such participants will be included in the vaccination group corresponding to the 
study  vaccination actually  received .
At least 1 temperature measurement obtained subsequent to study  intervention is required for 
inclusion in the analy sis of temperature.
9.6 Statistical Methods
Statistical testing and inference for safet y and immunogenicit y analyses are described in 
Section 9.6.1 and Section 9.6.2, respectivel y. Unless otherwise stated, all statistical tests will 
be conducted at th e α=0.05 (2- sided) level. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  61
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
9.6.1 Statistical Methods for Immunogenicity Analyses
This section describes the statistical methods that address the secondary and exploratory  
objectives about the immunogenicity anal yses to be performed for the Premature Infant 
Immunogenicit y Substudy .
For the Premature Infant Immunogenicit y Substudy ,evaluation of secondary  and exploratory  
endpoints regarding anti-PnPs seroty pe-specific IgG GMCs and OPA GMTs at 30 day s PD3, 
prior to Dose 4 and at 30 day s PD4 for the 15 seroty pes contained in the V114 group will be 
performed within each vaccination group separately . The point estimates will be calculated 
by [CONTACT_624761] (CIs) will be derived by  [CONTACT_624762] s of the mean of the natural log values 
based on the [ADDRESS_832342] method proposed by  
[CONTACT_93325] [CLOPPER, C. J. and PEARSON, E. S. 1934] .
A det ailed analy sis strategy  for immunogenicity  endpoints is listed in Table 3 .
Table 3 Analy sis Strategy  for Immunogenicit y Variables
Endpoint/Variable
(Description, Time Point)Primary vs. 
Supportive 
Approach†Statistical MethodAnalysis 
PopulationMissing Data 
Approach
Anti-PnPs IgG GMCs at 30 days 
PD3PDescriptive Statistics
(estimate, 95% CI)PP Missing data 
will not be 
imputed S FAS
Anti-PnPs IgG GMCs prior to 
Dose 4PDescriptive Statistics
(estimate, 95% CI)PP Missing data 
will not be 
imputed S FAS
Anti-PnPs IgG GMCs at 30 days 
PD4PDescriptive Statistics
(estimate, 95% CI)PP Missing data 
will not be 
imputed S FAS
Proportion of participants with 
anti-PnPs IgG ≥0.35 µg/mL at 
30days PD3P
Descriptive Statistics
(estimate, 95% CIǁ)PP
Missing data 
will not be 
imputedS FAS
S FAS
†P = Primary approach; S = Supportive approach. 
ǁWithin group summaries provided using exact method proposed by [CONTACT_93325].
CI = confidence interval; FAS = Full Analysis Set; GMC = Geometric Mean Concentration; 
IgG = Immunoglobulin G; PD = postdose; PnPs = pneumococcal polysaccharide; PP = Per -Protocol
9.6.[ADDRESS_832343]:   V114  62
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
The anal ysis of safet y results will follow a tiered approach (Table 4). The tiers differ with 
respect to the anal yses that will be performed. Adverse events (specific terms as well as 
system organ class terms) are either pre -specified as “Tier 1” endpoints, or will be classified 
as belonging to “Tier 2” or “Tier 3” based on the number of events observed. 
Tier [ADDRESS_832344] that are identified constitute “Tier 1” safet y 
endpoints that will be subject to inferential testing for statistical significance with p -values 
and 95% CI sto be provided for between- treatment differences in the proportion of 
participants with events; these anal yses will be performed using the Miettinen and Nurminen 
(M&N) method (1985), an unconditional, asy mptotic method. However, these p -values and 
CIsshould be regarded as helpful descriptive measures to be used in review, not formal 
methods for assessing the statistical significance of the between -treatment differences in AEs 
and safet y parameters. For this protocol, solicited injection- site AEs (redness, swelling, hard 
lump , and tenderness/pain) from Day 1 through Day 14 postvaccination and solicited 
systemic AEs (irritability, drowsiness, hives or welts, and appetite loss) from Day 1 through 
Day 14 postvaccination are considered Tier 1 events.
Tier 2 Events
Tier 2 parameters will be assessed via point estimates with 95% CI s provided for differences 
in the proportion of participants with events (also via the M&N method [1985 ])[Miettinen, 
O. and Nurminen, M. 1985] .
Membership in Tier [ADDRESS_832345] 1% ofthe participants in either treatment group 
exhibit the event. The threshold of at least 1%was chosen because when less than 1% of 
participants report AEs in both groups with more events in the V114 group, the 95% CI for 
the between -group difference in percent incidence will always include zero .Note that when 
less than 1% of participants report AEs in both groups but with more events in the 
Prevnar 13™ group or equal in both groups, the 95% CI for the between -group difference 
may exclude zero. However, the clinical significance of these differences is unknown given 
the small number of participants who report AEs i n this situation (fewer the 4 subjects in
each group) and;therefore , these AEs will be categorized as Tier 3 events. Because man y 
95% CIs for Tier [ADDRESS_832346] 1% of participants in any  treatment 
group, the broad AE categories consisting of the proportion of participants with any AE, a 
vaccine -related AE, an SAE, a vaccine -related SAE, discontinuation due to an AE, and the 
proportion of participants who died will be considered Tie r [ADDRESS_832347]:   V114  63
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Tier 3 Events
Safety  endpoints that are not Tier 1 or 2 events are considered Tier 3 events. Only point 
estimates by  [CONTACT_113825] 3 safet y parameters.
Table 4 Analy sis Strategy for Safety  Parameters
Safety 
Tier Safety Endpoint†p-Value95% CI fo r 
Between -
Group 
Com parisonDescriptive
Statistics
Tier 1Injection -siteredness/erythema (Days 1to14) X X X
Injection -siteswelling (Days 1to14) X X X
Injection -sitetenderness /pain (Days 1to14) X X X
Injection -site hard lump/induration (Day s 1 to 
14)X X X
Irritability (Days 1to14) X X X
Drow siness/somnolence (Days 1 to14) X X X
Hives or welts/urticaria (Days 1to14) X X X
Appetite loss/decreased appetite (Days 1to14) X X X
Tier 2Any AE†X X
Any Vaccine -Related AE†X X
Any SAE†X X
Any Vaccine -Related SAE†X X
Discontinuation due to AE†X X
Death†X X
Maximum temperature measurements meeting 
the Brighton Collaboration cut points (Days 1 
to 7) X X
Specific AEs by [CONTACT_3592]‡(incidence ≥4 of 
participants in one of the vaccination groups)X X
Tier 3Specific AEs by [CONTACT_3592]‡(incidence <4 of 
participants in all of the vaccination groups)X
†These endpoints are broad adverse event categories. For example, descriptive statistics for the safety 
endpoint of “Any AE” will provide the number and percentage of participants with at least one AE.
‡Includes only those endpoints not pre- specified as Tier 1 or not already pre -specified as Tier 2 endpoints.
AE = adverse event; CI = confidence interval; PT = preferred term; SAE = serious adverse event; 
SOC =system organ class; X = results will be provided
9.6.3 Demographic and Baseline Characteristics
The comparability  of the vaccination groups for each relevant demographic and baseline 
characteristic will be assessed by [CONTACT_93329]. No statistical hypothesis tests 
will be performed on these characteristics. The number and percentage of pa rticipants 
screened and randomized and the primary  reasons for screening failure and discontinuation 
will be display ed. Demographic variables (e .g., age, race, and gender, birth weight [kg], 
gestational age), baseline characteristics, prior and concomitant vaccinations and therapi[INVESTIGATOR_624750].
Demographic variables and baseline characteristics will also be summarized for the 
Premature Infant Immunogenicity  Substudy .  
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  64
PROTOCOL/AMENDMENT N O.: 031-[ADDRESS_832348] to enable a benefit -risk assessment.
Study  enrollment is likely  to be ongoing at the time of any  interim analy ses. Blinding to 
intervention assignment will be maintained at all investigational sites. The results of interim 
analyses will not be shared with the investigators prior to the completion of the study. 
Participant -level unblinding will be restricted t o an external unblinded statistician performing 
interim analy ses.
The DMC will serve as the primary  reviewer of the results of the safet y interim anal yses and 
will make recommendations for discontinuation of the study or protocol modifications to an 
execut ive committee of the Sponsor (see Appendix 1 for details on the Committees Structure 
for this study ). If the DMC recommends modifications to the design of the protocol or 
discontinuation of the study , this Executive Oversight Committee (EOC) of the Sponsor (and 
potentially  other limited Sponsor personnel) may  be unblinded to results at the intervention 
level in order to act on these recommendations. The extent to which individuals are 
unblinded with respect to results of interim anal yses will be documented by [CONTACT_171628]. Additional logistical details will be provided in the DMC Charter.
Intervention- level results from the safety  interim analy sis will be provided by  [CONTACT_252344]. Prior to final study unblinding, the external unblinded 
statistician will not be involved in any discussions regarding modifications to the protocol, 
statistical methods, identification of protocol deviations, or data validation efforts after the 
interim analy ses.
9.8 Multiplicity
No multiplicity  adjustment is planned as there is no formal h ypothesis testing.
9.9 Sample Size and Power Calculations
9.9.1 Sample Size and Power for Immunogenicity Analyses
Immunogenicit y anal yses are for Premature Infant I mmunogenicit y Substudy only and 
considered as secondary  objectives in this study . All immunogenicity  objectives are 
descriptive endpoints. The study  will randomize premature infants in a 1:1 ratio to either 
V114 or Prevnar 13™ vaccination group. The sample size of Premature Infa nt 
Immunogenicit y Substudy will be approximately  1% to 2% of the total enrolled participant s. 
The width of the within- group 95% CIs for the seroty pe-specific IgG GMCs depends on the  
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  65
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
sample size, variability  of the natural log concentrations, and the magnit ude of the IgG GMC. 
For demonstration, it is assumed that 25 participants in each vaccination group will be 
enrolled and 22 participants will be evaluable for PP immunogenicity  analy ses at 30days 
PD3, prior to Dose 4 , and 30days PD4 (based on the 90% eva luabilit y rate). The 95% CI s 
based on the assumed number of evaluable subjects for various h ypothetical IgG GMCs at [ADDRESS_832349] deviation 
estimates for the natural log titers are displayed in Table 5 .
Table 5 Within -Group 95% CI s for Vary ing Hy pothetical IgG GMCs and Vary ing 
Standard Deviations 
Standard Deviatio n of 
Natural Log Titers†Serotype -specific IgG GMCs†
1 5 10
V114 orPrevnar 13™ V114 orPrevnar 13™ V114 orPrevnar 13™
1.0 (0.64, 1.56 ) (3.21, 7.7 9) (6.42, 15.58 )
1.5 (0.51, 1.94 ) (2.57, 9.72 ) (5.14, 19.45 )
2.0 (0.41, 2.43 ) (2.06, 12.14 ) (4.12, 24.2 7)
Based on 22 evaluable participants in either V114 group or Prevnar 13™ group .
†The estimates of the standard deviation and IgG GMCs are representative of those observed in previous 
MSD study .
CI = confidence interval; GMC = Geometric Mean Concentration; IgG= Immunoglobulin G .
9.9.[ADDRESS_832350] udy 
population. Calculations below assume that 100% of the randomized participants will be 
evaluable for safet y analyses. There is an 80% chance of observing at least one SAE among 
2,000 participants in V114 group if the underl ying incidence of an SAE is 0 .08% (1 of every  
1243 participants receiving the vaccine). There is a 50% chance of observing at least 
one 
SAE among 2 ,000 participants in V114 group if the underl ying incidence of an SAE is 
0.03% (1 of every  2,886 participants receiving the vaccine). If n o SAEs are observed among 
2,000 participants, this study  will provide 97.5% confidence that the underly ing percentage 
of participants with an SAE is <0.18% (one in every  543 participants).
Table 6 summarizes the percentage point differences between the 2 vaccination groups that 
could be detected with 80% probability  for a variety  of hypothetical underly ing incidences of 
an AE. These ca lculations assume 2,000 participants in V114 group and 400 participants in 
Prevnar 13™ group, and are based on a 2- sided 5% alpha level. The calculations are based 
on an as ymptotic method proposed by [CONTACT_63541] (1990) [Farrington, C. P. 
1990] ; no multiplicity  adjustments were made. 
  055BNR
055BNR
06DW3Y
352'8&7 9 
[ZIP_CODE]&2/$0(1'0(1712 
9),1$/[ZIP_CODE]&2/ )(%
7DEOH 'LIIHUHQFHVLQ,QFLGHQFHRI$GYHUVH(YHQW5DWHV%HWZHHQ WKH9DFFLQDWLRQ
*URXSV7KDW&DQEH'HWHFWHG:LWKDQa3UREDELOLW\$VVXPLQJ VLGHG
$OSKD/HYHOZLWK3DUWLFLSDQWVLQ9*URXSDQG3DUWLF LSDQWVLQ
3UHYQDU*URXS
,QFLGHQFHRI$GYHUVH(YHQW 5LVN'LIIHUHQFH
9 3UHYQDU 3HUFHQWDJH3RLQWV
  
  
  
  
  
  
  
,QFLGHQFHVSUHVHQWHGKHUHDUHK\SRWKHWLFDODQGGRQRWUHSUHVHQW DFWXDODGYHUVHH[SHULHQFHVLQHLWKHUJURXS
%DVHGRQDQDV\PSWRWLFPHWKRGSURSRVHGE\)DUULQJWRQDQG0DQQLQ J>)DUULQJWRQ&3@
 6XEJURXS$QDO\VHV
6XEJURXSDQDO\VHVEDVHGRQVH[  ŧŦŮŢŭŦġŷŦųŴŶŴġŮŢŭŦ DQGUDFHZLOOEHSHUIRUPHGIRUVHOHFWHG
VDIHW\HQGSRLQWVVX[COMPANY_003]U\RI$(V 'HWDLOVRIVXEJURXSDQDO\VHV ZLOOEHGRFXPHQWHGLQWKH
V6$3
 &RPSOLDQFH0HGLFDWLRQ$GKHUHQFH7KHQXPEHUDQGSURSRUWLRQRIUDQGRPL]HGSDUWLFLSDQWVUHFHLYLQJ HDFKYDFFLQDWLRQZLOOEH
VX[COMPANY_003]UL]HG6HFWLRQ
 ([WHQWRI([SRVXUH7KHH[WHQWRIH[SRVXUHZLOOEHVX[COMPANY_003]UL]HGE\WKHQXPEHUDQGSUR SRUWLRQRIUDQGRPL]HG
SDUWLFLSDQWVDGPLQLVWHUHG9RU3UHYQDUDWHDFKYDFFLQDWLR QVFKHGXOH
 %15 %15':<
PRODUCT:   V114  67
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
10SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_832351] for Clinical Trials
[COMPANY_006] Sharp and Dohme Corp., a subsidiary of [COMPANY_006] & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participant s inclinical trials is the 
overriding concern in the design of clinical trials . In all cases, M SD clinical trials will be conducted in compliance 
with local and/or national regulations (eg, International Council for Harmonisation Good Clinical Practice [ICH -
GCP]) and in accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
[CONTACT_19481] (parties) employed f or their execution (eg, contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials , which are not under the 
full control of M SD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, 
efficacy, and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. 
Alternatively, M SDmay conduct outcomes research trials, trials to assess or validate various endpoint 
measures, or trials to determine patient preferences, etc.
The design (ie, participant population, duration, statistical power) must be adequate to address the specific
purpose of the trial. P articipants must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
MSD selects investigative sites based on medical expert[INVESTIGATOR_18700], access t o appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by M SD personnel to assess the ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative t rial sites are monitored to assess compliance with the trial protocol and general principles of 
Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data 
are verified versus source documentation according to standard operating procedures. Per M SD policies and 
procedures, if fraud, scientific/research misc onduct, or serious GCP -noncompliance is suspected, the issues 
areinvestigated. When necessary, the clinical site will be closed, the responsible regulatory authorities and 
ethics review committees notified . 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  68
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish primary and secondary results o f its registered trials of 
marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the 
extent scientifically appropriate, M SDseeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothesis testing , in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSD’s policy on authorship is consistent with the re commendations published by [CONTACT_26399] (ICMJE). In summary, authorship should reflect significant contri bution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. M SD funding of a trial will be acknowledged in 
publications.
III.Participant Protection
A. Ethics Committee Review (Institutiona lReview Board [IRB ]/Independent Ethics Committee [ IEC])
All clinical trials will be reviewed and approved by [CONTACT_2717]/IEC before being initiated at each site. Significant 
changes or revisions to the protocol will be approved by [CONTACT_63543], except 
changes required urgently to prot ect participant safety that may be enacted in anticipation of ethics committee 
approval. For each site, the ethics committee and M SDwill approve the participant informed consent form.
B. Safety
The guiding principle in decision -making in clinical trials i s that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local stand ard of care.
All p articipation in M SD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained . Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
[CONTACT_2371], only the investigator, Sponsor (or representative), ethics committee, and/or regulator y authorities will have 
access to confidential medical records t hat might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_63544] c ommittee.
IV. Financial Considerations
A. Paym ents to Investigators
Clinical trials are time -and labor -intensive. It is M SD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of M SD trials. M SD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. Ho wever, M SDmay compensate referring physicians for time spent 
on chart review to identify potentially eligible participants. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  69
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SDand that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from M SD trials will indicate M SD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (eg, to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices .
V. Investigator Commit ment
Investigators will be expected to review M SD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the 
Sponsor's responsibility  to determine, based on these regulat ions, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.
The investigator/subinvestigator(s) agree, if requested by  [CONTACT_19489] 2 1 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by  
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these pur poses. This may  involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.3 Data Protection
Participants will be assigned a unique identifier by [CONTACT_1034]. An y participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or an y information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  [CONTACT_624763] S ponsor, by  
[CONTACT_6667]/IEC members, and b y inspectors from regulatory authorities. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  70
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maintained in confidence, and such information will 
be divulged to the IRB, IEC,or similar or expert committee; affiliated institution and 
employ ees, only  under an appropriate understanding of confidentialit y with such board or 
committee, affiliated institution and employ ees. Data generated b y this study will be 
considered confidential by [CONTACT_093], except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory  authority  representatives may  consult and/or cop y study  documents to 
verify  worksheet/ CRF data. By  [CONTACT_17317], the participant agrees to this 
process. If study  documents will be photocopi[INVESTIGATOR_75311]/ CRF information, the participant will be identified b y unique code only; full 
names/initials will be masked prior to transmissi on to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study  in accordance with all applicable privacy  laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study . The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements b y requesting and maintaining reco rds of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies.
10.1.4 Committees Structure
[IP_ADDRESS] Scientific Advisory Committee
This study  was developed in collaboration with a Scientific Advisory  Committee (SAC). The 
SAC is comprise d of both Sponsor and non -Sponsor scientific experts who provide input 
with respect to study  design, interpretation of study  results, and subsequent peer -reviewed 
scientific publications.
[IP_ADDRESS] Executive Ov ersight Committee
The Executive Oversight Committee (EOC) is comprise d of members of Sponsor Senior 
Management. The EOC will receive and decide upon any  recommendations made by  [CONTACT_63547] . 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  71
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
[IP_ADDRESS] External Data Monitoring Committee
To supplement the routine study  monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study . The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in any other 
way (eg, they  cannot be study  investigators) and must have no competing interests that could 
affect their roles with respect to the study .
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safet y and the con tinued ethical integrity  of the study . Also, the DMC will review interim 
study  results, consider the overall risk and benefit to study  participants ( Section 9.7 I nterim 
Analy sis) and recommend to the EOC whether the study  should continue in accordance with
the protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study  governance structure; and requirements for and proper documentation 
of DMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by [CONTACT_63548].
10.1.[ADDRESS_832352] (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study  is solel y responsible for determinin g whether the stud yand its results are subject
to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study , will 
review this protocol and submit the informatio n necessary  to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to identify  potentiall y appropriate studies for their 
disease conditions and pur sue participation b y calling a central contact [CONTACT_126563]. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  72
PROTOCOL/AMENDMENT N O.: 031-[ADDRESS_832353] the study  in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of G CP
(eg, International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceutica ls for Human Use G CP: Consolidated Guideline and other generally  
accepted standards of GCP ); and all applicable federal, state and local laws, rules and 
regulations relating to the conduct of the clinical study .
The Code of Conduct, a collection of goals a nd considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored b y MSD, is provided i n this appendix 
under the Code of Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator b y the Sponsor.
The investigator will promptly  inform the Sponsor of an y regulatory authority inspection 
conducted for this study .
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulting 
from regulatory  authority inspection and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  authority . 
Persons debarred from conducting or working on clinical studies by  [CONTACT_624764] r’s studies. The investigator 
will immediately  disclose in writing to the Sponsor if any  person who is involved in 
conducting the study  is debarred or if any  proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
10.1.8 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verify ing that data entries are accurate and correct by  
[CONTACT_55896] y or electronically signing the CRF.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  73
PROTOCOL/AMENDMENT N O.: 031-[ADDRESS_832354] maintain accurate documenta tion (source data) that supports the 
information entered in the CRF.
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents.
Study  documentation wi ll be promptly and fully  disclosed to the Sponsor by [CONTACT_63551], 
copy ing, review, and audit at reasonable times b y representatives of the Sponsor or an y 
regul atory  authorities. The investigator agrees to promptly  take an y reasonable steps that are 
requested b y the Sponsor or any regulatory  authorit ies as a result of an audit or inspection to 
cure deficiencies in the stud y documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data.
Study  monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safet y and rights of participants are being protected; and that the 
study  is being conducted in accordance with the currentl y approved protocol and an y other 
study  agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including signed ICF, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 ye ars after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the Sponsor. No records may be 
transferred to another location or part y without written notification to the Sponsor.
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and study  records that include al lpertinent obse rvations on each 
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry, and should be expl ained if necessary  (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depending on the study . Also, current medical records must be available. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  74
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
10.1.10Study and Site Closure
The Sponsor or its designee may  stop the stud y or study site participation in the study for 
medical, safety , regulatory , administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurel y terminates a particular stud ysite, the Sponsor will 
promptly  notify  that study  site’s IRB/IEC. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  75
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
10.2 Appendix 2: Clinical Laboratory Tests
Not applicable. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  76
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definiti on
•An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study  intervention, whether or not considered related to the 
study  intervention.
•NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study intervention.
•NOTE: For purposes of AE definition, study  intervention (also referred to as Sponsor’s 
product) includes a ny pharmaceutical product, biological product, vaccine, diagnostic 
agent, or protocol specified procedure whether investigational or marketed (including 
placebo, active comparator product, or run -in intervention) , manufactured by , licensed 
by, provided by ,or distributed by  [CONTACT_63553] .
Events meeting the AE definition
•Any abnormal laboratory test results (hematology , clinical chemistry, or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurem ents), 
including those that worsen from baseline, or are considered clinicall y significant in the 
medical and scientific judgment of the investigator.
•Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequenc y and/or intensity  of the condition.
•New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
•Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interac tion.
•Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any  associated clinical sy mptoms or abnormal laboratory  results is reported using 
the terminology  “accidental or intentional overdose without adverse effect.”
    
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  77
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Events NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
•Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
•Surgery  planned prior to informed consent to treat a pre- existing condition that has not 
worsened.
•Refe r to Section 8.4.[ADDRESS_832355] medical occurrence that, at any dose:
1. Results in death
2. Is life -threatening
•The term “ life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
3. Requi res inpatient hospi[INVESTIGATOR_1081]
•Hospi[INVESTIGATOR_19357], regardless of length of stay, even if 
the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a pre -existing condition that has not 
worsened is not an SAE. A pre -existing condition is a clinical condition that is diagnosed 
prior to the use of an MSD product and is documented in the participant’s me dical 
history .
4. Results in persistent or significant disability/incapacity
•The term disability  means a substantial disruption of a person’s ability  to conduct normal 
life functions. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  78
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
•This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and 
accidental trauma (eg, sprained ankle) that may  interfere with or prevent every day life 
functions but do not constitute a substantial disruption.
5. Is a congenital anomaly/birth defect
•In offspring of participant taking the product regardless of time to diagnosis.
6. Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations su ch as important medical events that may not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_252313] 1 of the other 
outcomes listed in the above defi nition. These events should usually  be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or convulsions 
that do not result in h ospi[INVESTIGATOR_059], or development of drug dependency or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer
•Is associated with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory , and di agnostics reports) related to 
the event.
•The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  79
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
•It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
•There may  be instances when copi[INVESTIGATOR_63475] b y 
the Sponsor. I n this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copi[INVESTIGATOR_19361].
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. I n such cases, the diagnosis (not the 
individual sig ns/sy mptoms) will be documented as the AE/SAE.
Assessment of i ntensity
•An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
The investigator will make an assessment of intensity  for each AE and SAE (and other 
reportable safet y event) reported during the stud y and assign it to 1 of the following 
categories:
-Mild: An event that is easily  tolerated b y the participant, causing minimal discomfort 
and no t interfering with every day activities (for pediatric studies, awareness of 
symptoms, but easily  tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
every day activities (for pediatric studies definitel y acting like som ething is wrong).
-Severe: An event that prevents normal everyday  activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; and both AE and SAE can be assessed as sev ere (for 
pediatric studies, extremely distressed or unable to do usual activities).
•Injection site redness ,swelling , or hard lump from the day  of vaccination through Day  [ADDRESS_832356]:   V114  80
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Assessment of c ausality
•Did the Sponsor ’s product cause the AE?
•The determination of the likelihood that the Sponsor ’s product caused the AE will be 
provided b y an investigator who is a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causalit y noted on the AE 
form, ensures that a medically  qualified assessment of causalit y was done. This initia lled 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the relationship between the 
Sponsor ’s product and the AE; the greater the correlation with the components and 
their respective elements (in number and/or intensity ), the more likel y the Sponsor ’s 
product caused the AE :
-Exposure: Is there evidence that the participant was actuall y exposed to the 
Sponsor ’s product such as: reliable history , acceptable compliance assessment (diary , 
etc.), seroconversion or identification of vaccine virus in bodily  specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor ’s product? Is the time of onset of the AE compatible 
with a vaccine -induced effect?
-Likely Cause: Is the AE not reasonabl y explained by  [CONTACT_63556], other drug(s)/vaccine(s), or other host or environmental factors ?
-Rechallenge: Was th e participant re -exposed to the Sponsor ’s product in the study ?
-If yes, did the AE recur or worsen?
-If yes, this is a positive rechallenge.
-If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in de ath or permanent 
disability , or (2) the study  is a single -dose vaccine study ; or (3) Sponsor ’s product(s) is/are 
used only  1 time.)
NOTE: IF A RECHALLENGE IS PL ANNED FOR AN AE THAT WAS SERI OUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370] ’S PRODUCT, OR I F RE-EXPOSURE 
TO THE SPONSOR ’S PRODUCT POSES ADDITIONAL POTENTIAL SI GNIFICANT 
RISK TO THE PARTI CIPANT THEN THE RECHALLENGE MUST BE APPROVED I N 
ADVANCE BY [CONTACT_63557], AND IF REQUI RED, THE 
IRB/IEC . 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  81
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
-Consistency with study intervention profile :Is the clinical/pathological 
presentation of the AE consistent with previous knowledge regarding the Sponsor ’s 
product or drug class pharmacology  or toxicology?
-The assessment of relationship will be reported on the CRFs /worksheets b y an 
investigator who is a qualified phy sician according to his/her best clinical judgment, 
including consideration of the above elements.
-Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ’s product relationship).
-Yes, there is a reasonable possibility  of Sponsor ’s product relationship:
-There is evidence of exposure to the Sponsor ’s product. The temporal 
sequence of the AE onset relative to the administration of the Sponsor ’s 
product is reasonable. The AE is more li kely explained by [CONTACT_1034] ’s 
product than b y another cause.
-No, there is not a reasonable possibility  of Sponsor ’s product relationship:
-Participant did not receive the Sponsor ’s product OR temporal sequence of the 
AE onset relative to administration of the Sponsor ’s product is not reasonable 
OR the AE is more likely explained by  [CONTACT_26372]’s 
product. (Also entered for a participant with overdose without an associated 
AE.)
•For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
•There may  be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very i mportant 
that the investigator always make an assessment of causalit y for every event before the 
initial transmission of the SAE data to the Sponsor.
•The investigator may change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow -up report with the updated causality  assessment.
•The causality  assessment is [ADDRESS_832357]:   V114  82
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested b y Sponsor to 
elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathologica l examinations, or 
consultation with other health care professionals.
•New or updated information will be recorded in the CRF.
•The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety e vent reporting to Sponsor via electronic 
data 
collection t ool
•The primary  mechanism for reporting to the Sponsor will be the electronic data collection 
(EDC) tool.
•Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
•If the electronic s ystem is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
•Reference Section 8.4.1 for reporting time requirements.
•The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
•After the stud y is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry  of new data or changes to existing data.
•If a site receives a report of a new SAE from a study  participant or receives updated data 
on a previousl y reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
•Contacts for SAE reporting can be found in the Investigator Stud y File Binder (or 
equivalent). 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  83
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the prefer red method to transmit this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE data collection tool sent by [CONTACT_19515].
•Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the I nvestigator Study  File Binder (or equivalent). 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  84
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definition s, Collection, and Documentation
Not applicable. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  85
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing
Not applicable. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  86
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.Definitions
a.Biomarker: A biological molecule found in blood, other bod y fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease. A bi omarker may be 
used to see how well the body  responds to a treatment for a disease or condition .1
b.Pharmacogenomics: The investigation of variations of DNA and RNA characteristics as 
related to drug/vaccine response.2
c.Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug/vaccine response.2
d.DNA: Deox yribonucleic acid.
e.RNA: Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected in this study  as ou tlined in Section 8.8 will be 
used in various experiments to understand:
◦The biology  of how drugs/vaccines work
◦Biomarkers responsible for how a drug/vaccine enters and is removed b y the body
◦Other pathway s drugs/vaccines may  interact with
◦The biology  of disease
The specimen(s) may  be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately  
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by [CONTACT_18484] t hose working for or 
with the Sponsor.
3. Summary of Procedures for Future Biomedical Research.
a.Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in the 
future biomedical research substudy 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  87
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
b.Informed Co nsent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained during 
screening for protocol enrollment from all participants or legal guardians, at a study visit 
by [CONTACT_63559] d esignate. Informed consent for future biomedical 
research should be presented to the participants on the visit designated in the SoA. If 
delay ed, present consent at next possible Participant Visit. Consent forms signed b y the 
participant will be kept at the clinical study site under secure st orage for regulatory  
reasons.
A template of each stud y site’s approved informed consent will be stored in the Sponsor’s 
clinical document repository .
c.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for futur e biomedical r esearch will be captured in 
the eCRFs . Any specimens for which such an informed consent cannot be verified will be 
destroy ed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as outlined in 
the SoA. I n general, if additional blood specimens ar e being collected for future 
biomedical r esearch, these will usually  be obtained at a time when the participant is 
having blood drawn for other study  purposes.
4.Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant' clinical information with future test results. I n 
fact little or no research c an be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like gender, age, medical history  and intervention outcomes are 
critical to understanding clinical context of anal ytical results.
To maintain privacy  of information collect ed from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guide lines as described below.
At the clinical study  site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain an y personally 
identify ing information embedded within it. The link (or key ) between participant 
identifiers and this unique code will be held at the study  site. No personal identifiers will 
appear on the specimen tube. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  88
PROTOCOL/AMENDMENT N O.: 031-[ADDRESS_832358] party  (eg, a university  investigator) designated by 
[CONTACT_1034]. The investigator conducting the anal ysis will follow the Sponso r’s privacy  
and confidentialit y requirements. An y contracted third part y anal yses will conform to the 
specific scope o f anal ysis outlined in this substudy . Future biomedical r esearch 
specimens remaining with the third part y after specific anal ysis is performed will be 
reported to the Sponsor.
6.Withdrawal From Future Biomedical Research
Participants may  withdraw their consent for future biomedical research and ask that their 
biospecimens not be used for future biomedical r esearch. Participants may withdraw 
consent at an y time b y contact[CONTACT_154478] [INVESTIGATOR_63472]. If medical 
records for the main study are still available, the investigator will contact [CONTACT_90095] ([EMAIL_1250]). 
Subse quently , the participant's specimens will be flagged in the biorepository  and 
restricted to main stud y use only . If specimens were collected from study participants 
specificall y for future biomedical r esearch, these specimens will be removed from the 
biore pository  and destroyed. Documentation will be sent to the investigator confirming 
withdrawal and/or destruction, if applicable. It is the responsibility  of the investigator to 
inform the participant of completion of the withdrawal and/or destruction, if ap plicable. 
Any anal yses in progress at the time of request for withdrawal/destruction or alread y 
performed prior to the request being received b y the Sponsor will continue to be used as 
part of the overall research study  data and results. No new analy ses wo uld be generated 
after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study 
records) or the specimens have been completel y anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be processed.
7.Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository  for potential 
analysis for up to [ADDRESS_832359]:   V114  89
PROTOCOL/AMENDMENT N O.: 031-[ADDRESS_832360] results are accessible only to the
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highl y secure, and is 
accomplished using network securit y policies and practices based on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory  laboratory  studies will be reported to the 
participant, famil y, or physicians. Principle reasons not to info rm or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability , and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may  publish results, presen t 
results in national meetings, and make results accessible on a public website in order to 
rapi[INVESTIGATOR_252314]. Participants will not be 
identified by  [CONTACT_624765] s cientific 
publication or presentation.
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all participants diagnosed and treated o n Sponsor 
clinical studies for f uture biomedical r esearch.
11.Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been mini mized and are 
described in the future biomedical r esearch informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy concerns. Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality . In this highl y unlikely  situation, there is risk that the 
information, like all medical information, may  be misused.
12.Questions
Any questions related to the future biomedical research should be e mailed directly  to 
[EMAIL_1250]. 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  90
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
13.References
1.National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.International Conference on Harmonization [Internet] : E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Availabl e from 
http://www.ich.org/products/guidelines/efficacy /efficacy -single/article/definitions-
for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html 
3.Industry  Pharmacogenomics Working Group [Internet]: Understanding the I ntent, 
Scope and Public Health Benefits of Exploratory  Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Available at http://i- pwg.org/ 
4.Industry  Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for I RBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.org/ 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  91
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
10.7 Appendix 7: Country -specific Requirements
10.7.[ADDRESS_832361] for Malaysia
In addition to the safet y objectives presented in Section 3, the following safety  hypothesis 
will be added. This hy pothesis corresponds to the primary  safety  objective of the study .
Hypothesis:
V114 is well tolerated in healthy  infants .
The safet y endpoints, safety  anal ysis populations, and statistical methods fo r safet y anal yses 
used to evaluate this h ypothesis are described in Section 9.4.2, Section 9.5.2, and 
Section 9.6.2, respectively , and are the same as those being conducted for all participants in 
the study . 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  92
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
10.8 Appendix 8: Abbreviations
Abbreviation Expande d Term
AE adverse event 
APaT all participants as treated
CRF case report form
DMC Data Monitoring Committee 
DNA deoxyribonucleic acid 
ECG electrocardiogram 
ECL electrochemiluminescence
eCRF electronic Case Report Form
EDC electronic data collection 
ELISA enzyme -linked immunosorbent assay
EMA European Medicines Agency
EOC Executive Oversight Committee 
eVRC electronic Vaccination Report C ard
FAS full analysis set
FDAAA Food and Drug Administration Amendments Act
GCP Good Clinical Practice 
GMC geometric mean concentration
HIV human immunodeficiency virus
IB Investigator’s Brochure 
ICF Informed Consent Form 
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IgG immunoglobulin G
IPD invasive pneumococcal disease
IRB Institutional Review Board 
IRT Interactive response technology
M&N Miettinen and Nurminen
MOPA Multiplex Opsonophagocytic Assay
MSD [COMPANY_006] Sharp & Dohme Corp.
OPA Opsonophagocytic activity
PCV pneumococcal conjugate vaccine
PD3 postdose [ADDRESS_832362]:   V114  93
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
11REFERENCES
[Burton, Robert L . and Nahm, 
Moon H. 2006]Burton RL, Nahm MH. Development and 
validation of a fourfold multiplexed 
opsonization assay  (MOPA4) for 
pneumococcal antibodies. Clin Vaccine 
Immunol 2006;13(9):1004- 9.03QT2R
[Centers for Disease Control 
and Prevention 2008]Centers for Disease Control and Prevention 
(CDC). Invasive pneumococcal disease in 
children 5 years after conjugate vaccine 
introduction- eight states,1998 -2005. MMWR 
Morb Mortal Wkly  Rep. 2008 Feb 
15;57(6):144 -8.04KW8S
[Centers for Disease Control 
and Prevention 2015]Centers for Disease Control a nd Prevention. 
Epi[INVESTIGATOR_528850] -
preventable diseases. 13th ed. Hamborsk y J, 
Kroger A, Wolfe S, editors. Washington 
(DC): Department of Health and Human 
Services (HHS); c2015. Chapter 6, Vaccine 
administration; p. 79 -106.0508PV
[CLOPPER, C. J. and 
PEARSON, E. S. 1934]CLOPPER CJ, PEARSON ES. The use of 
confidence of fiducial limits illustrated in the 
case of the binomial. Biometrika 
1934;26(4):404- 13.03RRVC
[Drijkoningen, J. J 2014] Drijkoningen JJ, Rohde GG. Pneumococcal 
infection in adults: burden of disease. Clin 
Microbiol I nfect. 2014 May ;[ADDRESS_832363] 5:45 -
51.04NFHN
[Esposito, S., et al 2005] Esposito S, Pugni L , Bosis S, Proto A, Cesati 
L, Bianchi C, et al. Immunogenicity , safet y 
and tolerability  of heptavalent pneumococcal 
conjugate vaccine administered at 3, [ADDRESS_832364] -natally to pre- and full -term 
infants. Vaccine 2005;23:1703- 8.03QW8Q 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  94
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
[Farrell, D. J, et al 2007] Farrell DJ, Klugman KP, Pi[INVESTIGATOR_63489] M. 
Increased antimicrobial resistance among 
nonvaccine serot ypes of Streptococcus 
pneumoniae in the pediatric population after 
the introduction of [ADDRESS_832365] 
Dis J. 2007 Feb;26(2):123 -8.04KWD9
[Farrington, C. P. 1990] Farrington CP, Manning G. Test Statistics 
and Sample Size Formulae for Comparative 
Binomial Trials with Null Hy pothesis of 
Non- Zero Risk Difference or Non -Unity 
Relative Risk. Stat Med Vol. 9,1447 -1454 
(1990)04FS6L
[Guevara, M., et a l 2016] Guevara M, Barricarte A, Torroba L, Herranz 
M, Gil -Setas A, Gil F, et al. Direct, indirect 
and total effects of 13 -valent pneumococcal 
conjugate vaccination on invasive 
pneumococcal disease in children in Navarra, 
Spain, 2001 to 2014: cohort and ca se-control 
study . Euro Surveill. 2016;21(14).04KSQ3
[Hausdorff, W. P., et al 2000] Hausdorff WP, Bry ant J, Kloek C, Paradiso 
PR, Siber GR. The contribution of specific 
pneumococcal serogroups to different disease 
manifestations: implications for conjugat e 
vaccine formulation and use, part II. Clin 
Infect Dis. 2000 Jan;30(1):122 -40.04PJ70
[Hicks, L . A., et al 2007] Hicks LA, Harrison LH, Flannery B, Hadler 
JL, Schaffner W, Craig AS, et al. Incidence 
of Pneumococcal Disease Due to Non -
Pneumococcal Conjuga te Vaccine (PCV7) 
Seroty pes in the [LOCATION_002] during the Era 
of Widespread PCV7 Vaccination, [ADDRESS_832366] Dis 2007;196:1346 -54.03QT0G
[Jokinen, J., et al 2015] Jokinen J, Rinta -Kokko H, Siira L , Palmu 
AA, Virtanen MJ, Nohy nekH, et al. Impact 
of ten -valent pneumococcal conjugate 
vaccination on invasive pneumococcal 
disease in Finnish children a population -
based study . PLoS One. 2015 Mar 
17;10(3):e0120290.04KW7F 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  95
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
[Lepoutre, A., et al 2015] Lepoutre A, Varon E, Georges S, Dorle ans F, 
Janoir C, Gutmann L , et al. I mpact of the 
pneumococcal conjugate vaccines on 
invasive pneumococcal disease in [LOCATION_009], 
2001- 2012. Vaccine. 2015 Jan 3;33(2):359 -
66.04KW88
[Lexau, C. A., et al 2005] Lexau CA, Ly nfield R, Danila R, Pi[INVESTIGATOR_63466] T, 
Fackl am R, Farley  MM, et al. Changing 
epi[INVESTIGATOR_624751]. 
JAMA 2005;294(16):2043 -51.03RBPW
[Martinelli, D., et al 2014] Martinelli D, Pedalino B, Cappelli MG,
Caputi G, Sallustio A, Fortunato F, et al 
Towards the 13- valent pneumococcal 
conjugate universal vaccination: effectiveness 
in the transition era between PCV7 and 
PCV13 in I taly, 2010 -2013. Hum Vaccin 
Immunother. 2014;10(1):33- 9.04KW8B
[Metlay , J. P., e t al 2006] Metlay  JP, Fishman NO, Joffe M, Edelstein 
PH. I mpact of pediatric vaccination with 
pneumococcal conjugate vaccine on the risk 
of bacteremic pneumococcal pneumonia in 
adults. Vaccine 2006;24:468- 75.03RC46
[Miettinen, O. and Nurminen, 
M. 1985]Miettinen O, Nurminen M. Comparative 
Analy sis of Two Rates. Stat Med 1985;4:213 -
26.03QCDT
[Moore, M. R., et al 2015] Moore MR, L ink-Gelles R, Schaffner W, 
Lynfield R, Lexau C, Bennett NM, et al. 
Effect of use of 13 -valent pneumococcal 
conjugate vaccine i n children on invasive 
pneumococcal disease in children and adults 
in the [LOCATION_003]: analy sis of multisite, population -
based surveillance. Lancet I nfect Dis. 2015 
Feb 3. [Epub ahead of print].043MRP 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  96
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
[Moss, S. J., et al 2010] Moss SJ, Fenton AC, Toomey  JA, Grai nger 
AJ, Smith J, Gennery AR. Responses to a 
conjugate pneumococcal vaccine in preterm 
infants immunized at 2, 3, and 4 months of 
age. Clin Vaccine Immunol. 2010 
Nov;17(11):1810- 6.04ZGR6
[Palmu, A. A., et al 2015] Palmu AA, Kilpi [CONTACT_58465], Rinta -Kokko H, 
Nohy nek H, Toropainen M, Nuorti JP, et al. 
Pneumococcal conjugate vaccine and 
clinically  suspected invasive pneumococcal 
disease. Pediatrics. 2015 Jul;136(1):e22 -7.04KVRL
[Pi[INVESTIGATOR_63466], Tamara, et al 
2010]Pi[INVESTIGATOR_63466] T, Lexau C, Farley MM, Hadler J, 
Harrison LH , Bennett NM, et al. Sustained 
reductions in invasive pneumococcal disease 
in the era of conjugate vaccine. J I nfect Dis 
2010;201(1):32- 41.03R5S4
[Ruckinger, S., et al 2009] Ruckinger S, van der Linden M, Reinert RR, 
von Kries R, Burckhardt F, Siedler A. 
Reduction in the incidence of invasive 
pneumococcal disease after general 
vaccination with 7- valent pneumococcal 
conjugate vaccine in [LOCATION_013] . Vaccine 
2009;27:4136- 41.03QYQQ
[Shinefield, H., et al 2002] Shinefield H, Black S, Ray P, Fireman B, 
Schwal be J, L ewis E. Efficacy , 
immunogenicit y and safety of heptavalent 
pneumococcal conjugate vaccine in low birth 
weight and preterm infants. Pediatr Infect Dis 
J. 2002 Mar;21(3):182 -6.04ZGRL
[U.S. Food and Drug 
Administration 2009]U.S. Food and Drug Admini stration (CDER, 
CBER, CDRH). Guidance for industry  
patient -reported outcome measures: use in 
medical product development to support 
labeling claims [I nternet]. Washington: U.S. 
Department of Health and Human Services; 
2009. Available from: 
https://www.fda.gov/downloads/drugs/guidan
ces/ucm193282.pdf04MG9J 
  055BNR
055BNR
06DW3Y
PRODUCT:   V114  97
PROTOCOL/AMENDMENT N O.: 031-01  
V114 -031-01 FINAL PROTOCOL 11-FEB-2019
[Wagenvoort, G. H., et al 
2016]Wagenvoort GH, Knol MJ, de Melker HE, 
Vlaminckx BJ, van der Ende A, Rozenbaum  
MH, et al.  Risk and outcomes of invasive 
pneumococcal disease in adults with 
underly ing cond itions in the post -PCV7 era, 
The Netherlands. Vaccine. 2016 Jan 
12;34(3):334 -40.04KTDB
[Waight, P. A., et al 2015] Waight PA, Andrews NJ, L adhani SN, 
Sheppard CL, Slack MP, Miller E. Effect of 
the 13 -valent pneumococcal conjugate 
vaccine on invasive pneu mococcal disease in 
England and Wales 4 y ears after its 
introduction: an observational cohort study . 
Lancet Infect Dis. 2015 May ;15(5):535 -43.04KTF2
[Weiss, S., et al 2015] Weiss S, Falkenhorst G, van der Linden M, 
Imohl M, von Kries R. Impact of 10 -  and 13-
valent pneumococcal conjugate vaccines on 
incidence of invasive pneumococcal disease 
in children aged under 16 y ears in German y, 
2009 to 2012. Euro Surveill. 2015 Mar 
12;20(10):[ZIP_CODE].04KTFC
[Whitney , Cynthia G., et al 
2003]Whit ney CG, Farley  MM, Hadler J, Harrison 
LH, Bennett NM, Ly nfield R, et al. Decline 
in invasive pneumococcal disease after the 
introduction of protein -polysaccharide 
conjugate vaccine. N Engl J Med 
2003;348(18):1737 -46.03QT0D
[World Health Organization 
2005]World Health Organization.  WHO Expert 
Committee on Biological Standardization: 
fifty-fourth report. WHO technical report 
series, 927; Geneva 2005.03QTCN
[World Health Organization 
2008]World Health Organization. WHO/Health 
Canada Consultation on Serological Criteria 
for Evaluation and Licensing of New 
Pneumococcal Vaccines.  2008 Jul 7 -8. 
Ottawa, Canada, 2008:1- 39.03R0JC 
  055BNR
055BNR
06DW3Y
V114 PAGE 1 PROTOCOL NO 0 31-01
Supplemental SAP                                                                     22Mar 2021
Supplemental Statistical Analysis Plan (sSAP ) 
  05R8SF
06FCWL
V114 PAGE 2 PROTOCOL NO 0 31-01
Supplemental SAP                                                                     22Mar 2021
Table	of	Contents
1. INTRODUCTION .......................................................................................... 4
2.SUMMARY OF CHANGES .......................................................................... 4
2.1SUMMARY OF CHANGES FROM PROTOCOL SAP ............................... 4
2.2SUMMARY OF CHANGES FROM PREVIOUS VERSIONS OF THE 
SSAP ............................................................................................................... 5
3. ANALYTICAL AND METHODOLOGICAL DETAILS ............................. 6
3.1STATISTICAL ANALYSIS PLAN SUMMARY .........................................6
3.2RESPONSIBILITY FOR ANALYSES/IN -HOUSE BLINDING ................. 7
3.3HYPOTHESES/ESTIMATION .....................................................................7
3.4ANALYSIS ENDPOINTS ............................................................................. 7
3.4.1 Immunogenicity Endpoints ........................................................... 7
3.4.2 Safety Endpoints ........................................................................... 8
3.5ANALYSIS POPULATIONS ........................................................................8
3.5.1 Immunogenicity Analysis Populations .........................................8
3.5.2 Safety Analysis Populations ......................................................... 9
3.6STATISTICAL METHODS ......................................................................... 10
3.6.1 Statistical Methods for Immunogenicity Analyses ..................... 10
3.6.2 Statistical Methods for Safety Analyses .....................................12
3.6.3 Demographic and Baseline Characteristics ................................ 14
3.7INTERIM ANALYSES ................................................................................ 15
3.8MULTIPLICITY .......................................................................................... 15
3.9SAMPLE SIZE AND POWER CALCULATIONS .....................................15
3.9.1 Sample Size and Power for Immunogenicity Analyses .............. 15
3.9.2 Sample Size and Power for Safety Analyses .............................. 16
3.10 SUBGROUP ANALYSES .....................................................................18
3.11 COMPLIANCE (MEDICATION ADHERENCE) ................................ [ADDRESS_832367]	of	Tables
Table 1 Analysis Strategy for Immunogenicity Variables ................................................................ 11
Table 2 Limits of Quantitation for OPA and IgG Serotype -specific Responses ...................................... 12
Table 3 Analysis Strategy for Safety Parameters ............................................................................. 14
Table 4 Within -Group 95% CIs for Varying Hypothetical IgG GMCs and Varying Standard 
Deviations ......................................................................................................................................... 16
Table 5 Differences in Incidence of Adverse Event Rates Between the 2 Vaccination Groups That 
Can be Detected With an ~80% Probability (Assuming 2-sided 5% Alpha Level with 2000 
Participants in V114 Group and 400 Participants in Prevnar 13™ Group) ...................................... 18 
  05R8SF
06FCWL
V114 PAGE 4 PROTOCOL NO 0 31-01
Supplemental SAP                                                                     22Mar 2021
1.INTRODUCTION
This supplemental SAP (sSAP) is a companion document to the protocol . In addition to the information 
presented in the protocol SAP which provide sthe principal features of confirmatory analyses for this trial, 
thissSAP provide sadditional statistical analysis details/data derivations and document smodifications or 
additions to the analysis plan that are not “princip al” in nature andresult from information that wasnot 
available at the time of protocol finalization.
2.SUMMARY OF CHANGES 
2.1 Summary of Changes from Protocol SAP
A summary of changes is p rovided in the table below:
Section Description of Change Rational e
Section 3.4.2 Safety 
EndpointsAdded a paragraph to specify the timeframe 
associated with the reporting of AEs. Revisions made for clarity. 
Section 3.5.1 Immunogenicity 
Analysis PopulationsUpdated one sentence in this section from 
“The FAS population consists of all 
randomized participants who received all 
study vaccinations required at the time point 
for the analysis and have serology result” to 
“The FAS population cons ists of all 
randomized participants who received all 
study vaccinations required at the time point 
for the analysis and have at least one
serology result at the time point for the 
analysis. ”Revisions made to clarify the criteria for
inclusion in the FAS population .
Section 3.5.2 Safety Analysis 
PopulationUpdated one sentence in this section from 
“Safety analyses will be conducted in the All 
Participants as Treated (APaT) population,
which consists of all randomized participants 
who received at least one dose of study
vaccination ” to “Safety analyses will be 
conducted in the All Participants as Treated 
(APaT) population, which consists of all 
randomized participants who received at 
least one dose of study vaccination for the 
time point of interest. For saf ety analyses 
following any dose of PCV, participant s
vaccinated with PCV at any time point will 
be included. For safety analyses following 
each dose of PCV, participants vaccinated 
with PCV at that dose will be included.
Participants who inadvertently received both 
V114 and Prevnar 13™ during the study will 
be excluded from the analyses and will only 
be included in a separate AE listing. ”Revisions made to clarify the criteri afor 
inclusion in the APaT population. 
Section 3.[ADDRESS_832368] 
stratum will be used for analyses when mis -
stratification happens.Added to provide additional statistical 
analysis details/data derivations . 
  05R8SF
06FCWL
V114 PAGE 5 PROTOCOL NO 0 31-01
Supplemental SAP                                                                     22Mar 2021
Section 3.6.1 Statistical 
Methods for Immunogenicity 
AnalysesAdded a paragraph and a table (Table 2) to 
explain how values below the LLOQ or
above the ULOQ should be treated in 
various analyses.Added to provide additional statistical 
analysis details/data derivations.
Section 3.6.1 Statistical 
Methods for Immunogenicity 
AnalysesAdded a paragraph to provide Reverse 
Cumulative Distribution Curves for IgG 
concentrations and OPA Titers at 30 Days 
Postdose 3 and 30 Days Postdose 4 .Added to provide additional statistical 
analysis details/data derivations.
Section 3.6.2 Statistical 
Methods for Safety AnalysesAdded a paragraph to explain the rationale 
for not including vaccination -site AEs in the 
summary tables.Added to provide additional statistical 
analysis details/data derivations.
Section 3.6.[ADDRESS_832369] ical 
Methods for Safety AnalysesAdded a paragraph to explain the rationale 
for not including laboratory AEs in the 
summary tables.Added to provide additional statistical 
analysis details/data derivations.
Section 3.6.2 Statistical 
Methods for Safety AnalysesAdded a paragraph to describe an additional 
supportive analysis of the proportion of 
participants with solicited complaints using 
the data collected directly from participants 
via the VRC.Added to provide additional statistical 
analysis details/data derivations.
Section 3.6.3 Summaries of 
Demographic and Baseline 
CharacteristicsAdded a sentence to specify the age variable 
used for the analyses.Added to provide additional statistical 
analysis details/data derivations.
Section 3.10 Subgroup 
Analyse s Added details of subgroup analyses. Added to provide additional statistical 
analysis details/data derivations.
Throughout Corrected minor typographical and 
grammatical errors.Revisions made for accuracy. 
2.[ADDRESS_832370] version of the sSAP . 
  05R8SF
06FCWL
V114 PAGE 6 PROTOCOL NO 0 31-01
Supplemental SAP                                                                     22Mar 2021
3.ANALYTICAL AND METHODOLOGICAL DETAILS
3.1 Statistical Analysis Plan Summary
Key elements of the statistical analysis plan are summarized below; the comprehensive plan is provided 
in Sections 3.2 through 3.12.
Study Design Overview A Phase 3, Multicenter, Randomized, Double -blind, Active Comparator -
controlled Study to Evaluate the Safety and Tolerability of V114 in 
Healthy Infants (PN EU-LINK)
Intervention Assignment Approximately 2400 healthy infants approximately 2 months of age will 
be enrolled.
Full-term infants ( gestational age ≥37 weeks ) will be randomly 
assigned in a 5:1 ratio to a complete dosing schedule of V114 or 
Prevnar 13™. 
Premature infants ( gestational age <37 weeks) will be randomly 
assigned in a 1:1 ratio to a complete dosing schedule of V114 or 
Prevnar 13™
Analysis Populati ons Safety:  All Participants as Treated (APaT)
Immunogenicity: Per-Protocol (PP) and Full Analysis Set (FAS) 
population for the Premature Infant Immunogenicity Substudy
Primary Endpoint(s) Proportion of participants with solicited injection -site AEs 
(swelling, redness/erythema, tenderness/pain, and hard 
lump/induration ) from Day 1 through Day 14 following any 
vaccination with V114 or Prevnar 13™
Proportion of participants with solicited systemic AEs 
(irritability, drowsiness/somnolence, appetite lost/decreased 
appetite, and hives or welts/urticaria ) from Day 1 through Day 14 
following any vaccination with V114 or Prevnar 13™
Proportion of participants with vaccine -related SAEs from Day 1 
through completion of study participation
Key Secondary Endpoint(s) Premature Infant Immunogenicity Substudy only:
Anti-pneumococcal polysaccharide ( PnPs )serotype -specific 
Immunoglobulin G ( IgG) Geometric Mean Concentrations 
(GMCs )for the 15 serotypes contained in V114 at 30 days PD3, 
prior to Dose 4 and at 30 days PD4
Anti-PnPs serotype- specific IgG response rates (proportion of 
participants meeting serotype -specific IgG threshold value of 
≥0.35 μg/mL) for the 15 serotypes contain ed in V114 at 30 days 
PD3
Statistical Methods for Key 
Immunogenicity AnalysesImmunogenicity analyses will be conducted for each of the 15 
pneumococcal serotypes contained in V114 separately. To address the 
immunogenicity objectives, evaluation of the anti-PnPs serotype -specific 
IgG GMCs and response rates will be summarized descrip tively. 
Statistical Methods for Key 
Safety AnalysesP-values (Tier 1 endpoints) and 95% CIs (Tier 1 and Tier 2 endpoints) will 
be provided for between -vaccination group differences in the percentage 
of participants with events; these analyses will be performed using the 
M&N method [Ref. 5.4:03QCDT] .
Interim Analyses To support the periodic review of safety and tolerability data across the   
V114 Phase [ADDRESS_832371] to enable a benefit -
risk assessment .
Multiplicity No multiplicity adjustment is planned.
Sample Size and PowerImmunogenicity :
The immunogenicity objectives for this study are descriptive secondary 
objectives for the Premature Infant Immunogenicity Substudy only. The 
study will randomize premature infant participants in a 1:1 ratio to either 
the V114 or Prevnar 13™ vaccination group. The sample size of the 
Premature Infant Immunogenicity Substudy will be approximately 1% 
to 2% of overall participants .There is no hypothesis to be evaluated for  
the immunogenicity objectives. Section 3.9.1 provides information 
about the expected vari ability of the IgG GMC given the sample size.
Safety:
Section 3.9.2 provides information about the ability of this study to 
estimate the incidence of AEs within and between the vaccination 
groups.
3.2 Responsibility for Analyses/In -House Blinding
The statistical analysis of the data obtained from this study will be the responsibility of the Clinical 
Biostatistics department of the Sponsor.
This study will be conducted as a double -blind study under in -house blinding procedures. The official, 
final database wil l not be unblinded until medical/scientific review has been performed, protocol 
deviations have been identified, and data have been declared final and complete.
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for s tudy 
intervention assignment . Randomization will be implemented in an IRT.
Blinding issues related to the planned interim analyses are described in Section 3.7. 
3.3 HYPOTHESES/E STIMATION
Objectives of the study are stated in Section 3 ofthe protocol . There is no hypothesis to be evaluated in 
this study. 
3.4 ANALYSIS ENDPOINTS
Safety endpoints for all participants and immunogenicity endpoints for the Premature Infant 
Immunogenicity Substudy that will be evaluated for within -and/or between -treatment differences are 
listed below.
3.4.1 Immunogenicity Endpoints
The immunogenicity analyses are for the Premature Infant Immunogenicity Substudy only.  A 
description of immunogenicity assessments for the Premature Infant Immunogenicity Substudy is 
containe d in Section 8.2of the protocol . Immune responses will be measured for the 15 serotypes 
contained in V114 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F). 
  05R8SF
06FCWL
V114 PAGE 8 PROTOCOL NO 0 31-01
Supplemental SAP                                                                     22Mar 2021
The secondary immunogenicity analysis endpoints include:
Anti-PnPs serotype -specific Immunoglobulin G ( IgG) Geometric Mean Concentrations ( GMCs)
for the 15 serotypes contained in V114 at 30 days PD3, prior to Dose 4 and at 30 days PD4
Anti-PnPs serotype -specific IgG response rates (proportion of participants meeting serotype -
specific I gG threshold value of ≥0.35 μg/mL) for the 15 serotypes contained in V114 at 30 days 
PD3
The exploratory immunogenicity analysis endpoint includes:
Anti-PnPs serotype -specific OPA GMTs for the 15 serotypes contained in V114 at 30 days PD3, 
prior to Dose 4 and at 30 days PD4
3.4.2 Safety Endpoints
A description of safety measures is contained in Sections 8.3 and 8.4 ofthe protocol . The analysis of 
safety results is described in Section 3.6.2.
Safety and tolerability will be assessed by [CONTACT_624766] s and postvaccination temperature measurements following any vaccination with V114 or 
Prevnar 13™.
The safety analysis endpoints include:
Proporti on of participants with solicited injection -site AEs (swelling, redness/erythema, 
tenderness/pain, and hard lump/induration) from Day 1 through Day 14 following any 
vaccination with V114 or Prevnar 13™
Proportion of participants with solicited systemic AEs (irritability, drowsiness/somnolence, hives 
or welts/ urticaria , and appetite loss/ decreased appetite) from Day 1 through Day 14 following 
any vaccination with V114 or Prevnar 13™
Proportions of participants with the broad AE categories consisting of any AE, a vaccine -related 
AE, an SAE, an AE which is both vaccine -related and serious, and discontinuation due to an AE, 
and the proportion of participants who died
Participants body temperature measured Day 1 (day of vaccination) through Day 7 following 
any vaccination with V114 or Prevnar 13™
The timeframe associated with the reporting of AEs is consistent with the collection. Nonserious adverse 
events (NSAEs) are reported from Day 1 through Day 14 following each vaccination . SAEs are reported 
from D ay 1 through completion of study participation.
3.5 ANALYSIS POPULATIONS
3.5.1 Immunogenicity Analysis Populations 
  05R8SF
06FCWL
V114 PAGE 9 PROTOCOL NO 0 31-01
Supplemental SAP                                                                     22Mar 2021
The immunogenicity analyses will be performed for the Premature Infant Immunogenicity Substudy 
only. The Per -Protocol ( PP)population will serve as the primary population for the analysis of 
immunogenicity data in this study. The PP population consists of all randomized participants in the 
Premature Infant Immunogenicity Substudy without deviations from the protocol that may substantially 
affect the results of the immunogenicity endpoint(s). Potential deviations that may result in the exclusion 
of a participant from the PP population for all immunogenicity analyses include:
Failure to receive primary infant series vaccination (V114 or Prevnar 13™ for Doses 1, 2, and 3) 
as per randomization schedule
Receipt of prohibited medication or prohibited vaccine prior to study vaccination
Additional potential deviations that may result in the exclusion of a participant from the PP popula tion 
for specific immunogenicity analyses (depending on the time point for analysis) include:
Failure to receive required study vaccine (V114, Prevnar 13™) according to vaccination 
schedule at the time point for the analysis
Failure to receive the schedul ed doses of V114 or Prevnar 13™ (at least 28 days between Doses 
1 and 2 and between Doses 2 and 3 [for PD3 and pre -dose 4 analysis], 12 months to 1 day prior 
to 16 months of age for Dose 4 [for PD4 PP analyses])
Receipt of prohibited medication or prohibit ed vaccine prior to a blood sample collection
Collection of blood sample at the time point for the analysis outside of the pre -specified window 
(as described in Section 1.3ofthe protocol )
The final determination on protocol deviations, and thereby [CONTACT_941] c omposition of the PP population, will 
be made prior to the final unblinding of the database. Participants will be included in the vaccination 
group to which they are randomized for the analysis of immunogenicity data using the PP population.
A supportive a nalysis using the Full Analysis Set ( FAS)population will also be performed for the 
immunogenicity endpoints. The FAS population consists of all randomized participants who received all 
study vaccinations required at the time point for the analysis and hav e at least one serology result at the 
time point for the analysis. Participants will be included in the vaccination group to which they are 
randomized for the analysis of immunogenicity data using the FAS population.
3.5.2 Safety Analysis Populations
Safety anal yses will be conducted in the All Participants as Treated ( APaT )population, which consists 
of all randomized participants who received at least one dose of study vaccination for the time point of 
interest . For safety analyses following any dose of PCV, pa rticipant svaccinated with PCV at any time
point will be included. For safety analyses following each dose of PCV, participants vaccinated with 
PCV at that dose will be included. Participants who inadvertently received both V114 and Prevnar 13™ 
during the study will be excluded from the analyses and will only be included in a separate AE listing. 
Participants will be included in the group corresponding to the study vaccination they actually received 
for the analysis of safety data using the APaT population. This will be the group to which they are  
  05R8SF
06FCWL
V114 PAGE [ADDRESS_832372] study vaccination; such participants will be 
included in the vaccination group corresponding to the study vaccination actually received.
At least 1 t emperature measurement obtained subsequent to study intervention is required for inclusion 
in the analysis of temperature.
3.6 STATISTICAL METHODS
Statistical testing and inference for safety and immunogenicity analyses are described in Section 3 .6.1 
and Section  3.6.2, respectively. Unless otherwise stated, all statistical tests will be conducted at the 
α=0.05 (2 -sided) level.
The correct stratum will be used for analysis regardless of the assigned stratum at randomization  (ie, 
stratification error s will be corrected for the purposes of analysis) .
3.6.1  Statistical Methods for  Immunogenicity Analyses
This section describes the statistical methods that address the secondary  and exploratory  objectives 
about the immunogenicity analyses to be performed for the  Premature Infant Immunogenicity Substudy . 
For the Premature Infant Immunogenicity Substudy, evaluation of secondary and exploratory endpoints 
regarding anti -PnPs serotype -specific IgG GM Cs and OPA GMTs at 30 days PD3, prior to Dose 4 and 
at 30 days PD4 for the 15 serotypes contained in the V114 group will be performed within each 
vaccination group separately. The point estimates will be calculated by [CONTACT_624767] (CIs) will be derived by [CONTACT_624768] 1- sample t -distribution. For the secondary 
endpoints regarding anti -PnPs serotype- specific IgG resp onse rates at [ADDRESS_832373] method 
proposed by [CONTACT_93325] [Ref. 5.4: 03RRVC] .
A detailed analys is strategy for immunogenicity endpoints is listed in Table  1. 
  05R8SF
06FCWL
V114 PAGE 11 PROTOCOL NO 0 31-01
Supplemental SAP 22Mar 2021
Table 1 Analysis Strategy for Immunogenicity Variables
Endpoi nt/Variable
(Description, Time Point)Primary vs. 
Supportive 
Approach†Statistical MethodAnalysis 
PopulationMissing Data 
Approach
Anti-PnPs IgG GMCs at 30 days PD3PDescriptive Statistics
(estimate, 95% CI)PP Missing data 
will not be 
imputed S FAS
Anti-PnPs IgG GMCs prior to Dose 4PDescriptive Statistics
(estimate, 95% CI)PP Missing data 
will not be 
imputed S FAS
Anti-PnPs IgG GMCs at 30 days PD4PDescriptive Statistics
(estimate, 95% CI)PP Missing data 
will not be 
imputed S FAS
Proportion of participants with anti -PnPs 
IgG ≥0.35 µg/ mL at 30 days PD3PDescriptive Statistics
(estimate, 95% CIǁ)PP Missing data 
will not be 
imputed S FAS
†P = Primary approach; S = Supportive approach.
ǁWithin group summaries provided using exact method proposed by [CONTACT_93325].
CI = confidence interval; FAS = Full Analysis Set; GMC = Geometric Mean Concentration; IgG=Immunoglobulin G;
PD = postdose; PnPs = pneumococcal polysaccharide; PP = Per -Protocol
The detectable ranges for OPA and IgG responses differ across serotypes. The limits of quantitation define 
the range of responses over which the assay provides precise and accurate measurements. Table 2 gives 
the limits of quantitation defined for each serotype for OPA and IgG responses. For responses smaller 
than the lower limit of quantitation (LLOQ) , half of the LLOQ is used for analysis when calculating the 
OPA GMTs and IgG GMCs. For OPA andIgG responses that are larger than the upper limit of quantita tion 
(ULOQ) , a value equal to ULOQ + 1 is used for analysis. 
  05R8SF
06FCWL
V114 PAGE 12 PROTOCOL NO 0 31-01
Supplemental SAP 22Mar 2021
Table 2 Limits of Quantitation for OPA and IgG Serotype -specific Responses
OPA IgG
Serotype LLOQ (1/dil) ULOQ (1/dil) LLOQ (µg/mL) ULOQ (µg/mL)
1 9 30,213 0.05 850
3 19 30,564 0.05 145
4 34 137,160 0.05 173
5 27 119,016 0.10 368
6A 232 210,600 0.05 393
6B 40 105,840 0.05 341
7F 61 251,235 0.05 830
9V 151 224,316 0.05 644
14 62 281,637 0.05 1,520
18C 115 445,230 0.05 730
19A 31 128,304 0.05 1,387
19F 113 158,841 0.05 1,461
22F 15 229,338 0.05 1,054
23F 55 251,829 0.05 595
33F 20 399,600 0.05 833
IgG = immunoglobulin G; LLOQ = lower limit of quantitation; OPA= opsonophagocytic activity; ULOQ = upper 
limit of quantitation.
Reverse Cumulative Distribution Curves for IgG concentrations and OPA Titers at 30 Days Postdose 3
and 30 Days Postdose 4 will be graphically displayed by [CONTACT_93326].
3.6.2 Statistical Methods for Safety Analyses
Safety and tolerability will be assessed by [CONTACT_624769].
The analysis of safety results will follow a tiered approach (Table 3).The tiers differ with respect to the 
analyses that will be performed. Adverse events (specific terms as well as system organ class terms) are 
either pre -specified as “Tier 1” endpoints, or will be classified as belonging to “Tier 2” or “Tier 3” based 
on the number of events observed. 
Tier [ADDRESS_832374] that are identified constitute “Tier 1” safety endpoints that 
will be subject to inferential testing for statistical significance with p -values and 95% CIs to be prov ided 
for between- treatment differences in the proportion of participants with events; these analyses will be  
  05R8SF
06FCWL
V114 PAGE 13 PROTOCOL NO 0 31-01
Supplemental SAP 22Mar 2021
performed using the Miettinen and Nurminen (M&N) method (1985), an unconditional, asymptotic 
method. However, these p- values and CIs should be rega rded as helpful descriptive measures to be used 
in review, not formal methods for assessing the statistical significance of the between -treatment 
differences in AEs and safety parameters. For this protocol, solicited injection -site AEs (redness, 
swelling, hard lump, and tenderness/pain) from Day 1 through Day 14 postvaccination and solicited 
systemic AEs (irritability, drowsiness, hives or welts, and appetite loss) from Day 1 through Day 14 
postvaccination are considered Tier 1 events.
Tier 2 Events
Tier 2 parameters will be assessed via point estimates with 95% CIs provided for differences in the 
proportion of participants with events (also via the M&N method [1985]) [Ref. 5.4: 03QCDT] .
Membership in Tier [ADDRESS_832375] 1% of the participants in either treatment group exhibit the 
event. The threshold of at least 1% was chosen because when less than 1% of participants report AEs in 
both groups with more events in the V114 group, the 95% CI for the be tween -group difference in 
percent incidence will always include zero. Note that when less than 1% of participants report AEs in 
both groups but with more events in the Prevnar 13™ group or equal in both groups, the 95% CI for the 
between -group difference m ay exclude zero. However, the clinical significance of these differences is 
unknown given the small number of participants who report AEs in this situation ( 1% of the participants 
in either treatment group ) and; therefore, these AEs will be categorized as Tier 3 events. Because many 
95% CIs for Tier [ADDRESS_832376] 1% of participants in any treatment group, the broad 
AE categories consisting of the proportion of participants with any AE, a vaccine -related AE, an SAE, a 
vaccine -related SAE, discontinuation due to an AE, and the proportion of participants who died will be 
considered Tier 2 endpoints. 
Tier 3 Events
Safety endpoints that are not Tier 1 or 2 events are co nsidered Tier 3 events. Only point estimates by 
[CONTACT_113825] 3 safety parameters. 
  05R8SF
06FCWL
V114 PAGE 14 PROTOCOL NO 0 31-01
Supplemental SAP 22Mar 2021
Table 3 Analysis Strategy for Safety Parameters
Safety 
Tier Safety Endpoint†p-Value95% CI fo r 
Between -
Group 
ComparisonDescriptive
Statistics
Tier 1Injection -siteredness/erythema (Days 1to14) X X X
Injection -siteswelling (Days 1to14) X X X
Injection -sitetenderness /pain (Days 1to14) X X X
Injection -site hard lump/induration (Days 1 to 
14)X X X
Irritability (Days 1to14) X X X
Drowsiness/somnolence (Days 1 to14) X X X
Hives or welts/urticaria (Days 1to14) X X X
Appetite loss/decreased appetite (Days 1to14) X X X
Tier 2Any AE†X X
Any Vaccine -Related AE†X X
Any SAE†X X
Any Vaccine -Related SAE†X X
Discontinuation due to AE†X X
Death†X X
Maximum temperature measurements meeting 
the Brighton Collaboration cut points (Days 1 to 
7) X X
Specific AEs by [CONTACT_3592]‡(incidence ≥1%
of participants in one of the vaccination groups)X X
Tier 3Specific AEs by [CONTACT_3592]‡(incidence <1%
of participants in all of the vaccination groups)X
†These endpoints are broad adverse event categories. For example, descriptive statistics for the safety 
endpoint of “Any AE” will provide the number and percentage of participants with at least one AE.
‡Includes only those endpoints not pre -specified as Tier 1 or not already pre -specified as Tier 2 endpoints.
AE = adverse event; CI = confidence interval; PT = preferred term; SAE = serious adverse event; 
SOC =system or gan class; X = results will be provided
Laboratory AEs will not be reported in summary tables as laboratory testing is not performed as part of 
the study and thus such AEs would only be reported spontaneously. A listing of laboratory AEs will be 
provided.
A supportive analysis comparing the proportion of participants reporting each of the solicite d complaints 
on the VRC will be conducted in support of the primary safety analyses that are based on solicited AEs. 
This supportive analysis will use the methodology specified in Table 3forsolicited AEs. The analysis 
will be conducted on the subset of the APaT population who entered solicited complaints data on the 
VRC.
3.6.3 Demographic and Baseline Characteristics
The comparability of the vaccination groups for each relevant demographic and bas eline characteristic 
will be assessed by [CONTACT_93329]. No statistical hypothesis tests will be performed on these 
characteristics. The number and percentage of participants screened and randomized and the primary 
reasons for screening failure and discontinuation will be displayed. Demographic variables (e.g., age, 
race, gender, and gestational age), baseline characteristics, prior and concomitant vaccinations and 
therapi[INVESTIGATOR_624752].  
  05R8SF
06FCWL
V114 PAGE [ADDRESS_832377] to enable a benefit -risk assessment.
Study enrollment is likely to be ongoing at the time of any interim analyses. Blinding to intervention 
assignment will be maintained at all investigational sites. The results of interim analyses will not be 
shared with the investigators prior to the completion of the study. Participant -level unblinding will be 
restricted to an external unblinded statistician performing interim analyses.
The DMC will serve as the primary reviewer of the results of the safety interim analyses and will make 
recommendations for discontinuation of the study or proto col modifications to an executive committee 
of the Sponsor (see Appendix 1 for details on the Committees Structure for this study). If the DMC 
recommends modifications to the design of the protocol or discontinuation of the study, this Executive 
Oversight Committee (EOC) of the Sponsor (and potentially other limited Sponsor personnel) may be 
unblinded to results at the intervention level in order to act on these recommendations. The extent to 
which individuals are unblinded with respect to results of interi m analyses will be documented by [CONTACT_93330]. Additional logistical details will be provided in the DMC Charter.
Intervention- level results from the safety interim analysis will be provided by [CONTACT_624770]. Prior to final study unblinding, the external unblinded statistician will not be 
involved in any discussions regarding modifications to the protocol, statistical methods, identification of 
protocol deviations, or data validation efforts after the interim analyses.
3.8 MULTIPLICITY
No multiplicity adjustment is planned as there is no formal hypothesis testing.
3.9 SAMPLE SIZE AND POWER CALCULATIONS
3.9.1 Sample Size and Power for Immunogenicity Analyses
Immunogenicity analyses are for Premature Infant Immunogenicity Substudy only and considered as 
secondary objectives in this study. All immunogenicity objectives are descriptive endpoints. The study 
will randomize premature infants in a 1:1 ratio to either V114 or Prevnar 13™ vaccination group. The 
sample size of Premature Infant Immunogenicity Substudy will be approximately 1% to 2% of the total  
  05R8SF
06FCWL
V114 PAGE 16 PROTOCOL NO 0 31-01
Supplemental SAP                                                                     22Mar 2021
enrolled participants. The width of the within -group 95% CIs for the serotype -specific IgG GMCs depends 
on the s ample size, variability of the natural log concentrations, and the magnitude of the IgG GMC. For 
demonstration, it is assumed that 25 participants in each vaccination group will be enrolled and 22 
participants will be evaluable for PP immunogenicity analys es at 30days PD3, prior to Dose 4, and 30 
days PD4 (based on the 90% evaluability rate). The 95% CIs based on the assumed number of evaluable 
participants for various hypothetical IgG GMCs at [ADDRESS_832378] deviation estimates for the natural log titers are displayed in Table 4.
Table 4 Within -Group 95% CIs for Varying Hypothetical IgG GMCs and Varying Standard 
Deviations 
Standard Deviation of 
Natural Log Titers†Serotype-specific IgG GMCs†
1 5 10
V114 or Prevnar 13™ V114 or Prevnar 13™ V114 or Prevnar 13™
1.0 (0.64, 1.56) (3.21, 7.79) (6.42, 15.58)
1.5 (0.51, 1.94) (2.57, 9.72) (5.14, 19.45)
2.0 (0.41, 2.43) (2.06, 12.14) (4.12, 24.27)
Based on 22 evaluable participants in either V114 group or Prevnar 13™ group .
†The estimates of the standard deviation and IgG GMCs are representative of those observed in previous MSD study.
CI = confidence interval; GMC = Geometric Mean Concentration; IgG= Immunoglobulin G .
3.9.[ADDRESS_832379] one SAE in this study depends on the number of participants 
vaccinated and the underlying incidence of participants with an SAE in the study population. 
Calculations below assume that 100% of the randomized participant s will be evaluable for safety 
analyses. There is an 80% chance of observing at least one SAE among 2,000 participants in V114 
group if the underlying incidence of an SAE is 0.08% (1 of every 1243 participants receiving the 
vaccine). There is a 50% chance of observing at least one SAE among 2,000 participants in V114 group 
if the underlying incidence of an SAE is 0.03% (1 of every 2,886 participants receiving the vaccine). If 
no SAEs are observed among 2,000 participants, this study will provide 97.5% confi dence that the 
underlying percentage of participants with an SAE is <0.18% (one in every 543 participants). 
  05R8SF
06FCWL
V114 PAGE 17 PROTOCOL NO 0 31-01
Supplemental SAP 22Mar 2021
Table 5 summarizes the percentage point  differences between the 2 vaccination groups that could be 
detected with 80% probability for a variety of hypothetical underlying incidences of an AE. These 
calculations assume 2,000 participants in V114 group and 400  participants in Prevnar  13™ group, and 
are based on a 2- sided 5% alpha level. The calculations are based on an asymptotic method proposed by 
[CONTACT_63541] (1990) [Ref.  5.4: 04FS6L] ; no multiplicity adjustments were made. 
  05R8SF
06FCWL
V114 PAGE 18 PROTOCOL NO 0 31-01
Supplemental SAP                                                                     22Mar 2021
Table 5 Differences in Incidence of Adverse Event Rates Between the 2 Vaccination Groups That 
Can be Detected With an ~80% Probability (Assuming 2 -sided 5% Alpha Level with 2000 Participants 
in V114 Group and 400 Participants in Prevnar 13™ Group)
Incidence of Adverse Event Risk Difference
V114 (%) Prevnar 13™ (%) Percentage Points
1.6 0.1 1.5
4.9 2 2.9
9.0 5 4.0
15.2 10 5.2
21.0 15 6.0
26.6 20 6.6
37.3 30 7.3
Incidences presented here are hypothetical and do not represent actual adverse experiences in either group.
Based on an asymptotic method proposed by [CONTACT_63541] (1990) [Ref. 5.4:04FS6L]
3.10 SUBGROUP ANALYSES
An overall summary of AEs and a summary of solicited AEs following any vaccination will be provided 
for each subgroup (point estimates only) with ≥5% of the total number of randomized participants in 
each vaccination group (except subgroups based on gestat ional age , which will be provided regardless of 
the percentage of the total number of randomized participants in each vaccination group).
The following subgroups are planned for evaluation:
Ethnicity (Hispanic or Latino, Not Hispanic or Latino)
Race ( American Indian or Alaska Native, Asian, Black or African American, Multiple, Native 
Hawaiian or Other Pacific Islander, White )
Sex ( Female, Male)
Gestational age < 37 weeks (yes/no)
3.11 COMPLIANCE (MEDICATION ADHERENCE)
The number and proportion of randomized participants receiving each vaccination will be summarized 
(Section 3.12).
3.12 EXTENT OF EXPOSURE
The extent of exposure will be summarized by [CONTACT_624771] V114 or Prevnar 13™ at each vaccination schedule . 
  05R8SF
06FCWL
V114 PAGE [ADDRESS_832380] OF REFERENCES 
[Ref. 5.4: 03QCDT] Miettinen O, Nurminen M. Comparative Analysis 
of Two Rates. Stat Med 1985;4:213 -26.
[Ref. 5.4:03RRVC] Clopper CJ, Pearson ES. The use of confidence of 
fiducial limits illustrated in the case of the 
binomial. Biometrika 1934;26(4):404- 13.
[Ref. 5.4:04FS6L] Farrington CP, Manning G. Test Statistics and 
Sample Size Formulae for Comparative Binomial 
Trials with Null Hypothesis of Non- Zero Risk 
Difference or Non- Unity Relative Risk. Stat Med 
Vol. 9,1447 -1454 (1990) 
  05R8SF
06FCWL